Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2021 | Apr. 30, 2021 | |
Document and Entity Information | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2021 | |
Document Transition Report | false | |
Entity File Number | 001-16391 | |
Entity Registrant Name | Axon Enterprise, Inc. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 86-0741227 | |
Entity Address, Address Line One | 17800 North 85th Street | |
Entity Address, City or Town | Scottsdale | |
Entity Address, State or Province | AZ | |
Entity Address, Postal Zip Code | 85255 | |
City Area Code | 480 | |
Local Phone Number | 991-0797 | |
Title of 12(b) Security | Common Stock, $0.00001 Par Value | |
Trading Symbol | AXON | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 64,684,364 | |
Entity Central Index Key | 0001069183 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2021 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Current assets: | ||
Cash and cash equivalents | $ 154,822 | $ 155,440 |
Short-term investments | 440,842 | 406,525 |
Accounts and notes receivable, net of allowance of $1,796 and $2,105 as of March 31, 2021 and December 31, 2020, respectively | 185,373 | 229,201 |
Contract assets, net | 72,472 | 63,945 |
Inventory | 89,657 | 89,958 |
Prepaid expenses and other current assets | 43,063 | 36,883 |
Total current assets | 986,229 | 981,952 |
Property and equipment, net | 112,119 | 105,494 |
Deferred tax assets, net | 46,403 | 45,770 |
Intangible assets, net | 8,642 | 9,448 |
Goodwill | 25,194 | 25,205 |
Long-term investments | 78,464 | 90,681 |
Long-term notes receivable, net | 18,546 | 22,457 |
Long-term contract assets, net | 26,341 | 20,099 |
Other assets | 102,920 | 79,917 |
Total assets | 1,404,858 | 1,381,023 |
Current liabilities: | ||
Accounts payable | 19,791 | 24,142 |
Accrued liabilities | 41,097 | 59,843 |
Contract with customer, liability, current | 165,086 | 163,959 |
Other current liabilities | 5,667 | 5,431 |
Total current liabilities | 239,775 | 256,331 |
Deferred revenue, net of current portion | 116,107 | 111,222 |
Liability for unrecognized tax benefits | 4,697 | 4,503 |
Long-term deferred compensation | 4,825 | 4,732 |
Deferred tax liability, net | 684 | 649 |
Other long-term liabilities | 27,866 | 27,331 |
Total liabilities | 393,954 | 404,768 |
Commitments and contingencies (Note 11) | ||
Stockholders' equity: | ||
Preferred stock, $0.00001 par value; 25,000,000 shares authorized; no shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively | ||
Common stock, $0.00001 par value; 200,000,000 shares authorized; 64,673,091 and 63,766,555 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively | 1 | 1 |
Additional paid-in capital | 1,044,724 | 962,159 |
Treasury stock at cost, 20,220,227 shares as of March 31, 2021 and December 31, 2020 | (155,947) | (155,947) |
Retained earnings | 121,984 | 169,901 |
Accumulated other comprehensive income | 142 | 141 |
Total stockholders' equity | 1,010,904 | 976,255 |
Total liabilities and stockholders' equity | 1,404,858 | 1,381,023 |
Current portion of deferred revenue | ||
Current liabilities: | ||
Contract with customer, liability, current | 165,086 | 163,959 |
Customer deposits | ||
Current liabilities: | ||
Contract with customer, liability, current | $ 8,134 | $ 2,956 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Statement of Financial Position [Abstract] | ||
Allowance on accounts receivable | $ 1,796 | $ 2,105 |
Preferred stock, par value (in dollars per share) | $ 0.00001 | $ 0.00001 |
Preferred stock, shares authorized (in shares) | 25,000,000 | 25,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.00001 | $ 0.00001 |
Common stock, shares authorized (in shares) | 200,000,000 | 200,000,000 |
Common stock, shares issued (in shares) | 64,673,091 | 63,766,555 |
Common stock, shares outstanding (in shares) | 64,673,091 | 63,766,555 |
Treasury stock, shares (in shares) | 20,220,227 | 20,220,227 |
Unaudited Condensed Consolidate
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Net sales | $ 195,019 | $ 147,162 |
Cost of sales | 71,666 | 58,554 |
Gross margin | 123,353 | 88,608 |
Sales, general and administrative | 126,597 | 63,027 |
Research and development | 47,018 | 26,381 |
Total operating expenses | 173,615 | 89,408 |
Income (loss) from operations | (50,262) | (800) |
Interest and other income, net | 585 | 941 |
Income (loss) before provision for income taxes | (49,677) | 141 |
Provision for (benefit from) income taxes | (1,760) | (3,933) |
Net income (loss) | $ (47,917) | $ 4,074 |
Net income (loss) per common and common equivalent shares: | ||
Basic (in dollars per share) | $ (0.75) | $ 0.07 |
Diluted (in dollars per share) | $ (0.75) | $ 0.07 |
Weighted average number of common and common equivalent shares outstanding: | ||
Basic (in shares) | 64,036 | 59,609 |
Diluted (in shares) | 64,036 | 60,394 |
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) | ||
Net income (loss) | $ (47,917) | $ 4,074 |
Foreign currency translation adjustments | 1 | (2,372) |
Comprehensive income (loss) | (47,916) | 1,702 |
Product | ||
Net sales | 140,886 | 107,288 |
Cost of sales | 58,616 | 48,884 |
Service | ||
Net sales | 54,133 | 39,874 |
Cost of sales | $ 13,050 | $ 9,670 |
Unaudited Condensed Consolida_2
Unaudited Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands | Cumulative Effect Period Of Adoption Adjusted BalanceRetained Earnings | Cumulative Effect Period Of Adoption Adjusted Balance | Common Stock | Additional Paid-in Capital | Treasury Stock | Retained Earnings | Accumulated Other Comprehensive Income | Total |
Beginning balance (in shares) at Dec. 31, 2019 | 59,497,759 | 20,220,227 | ||||||
Beginning balance at Dec. 31, 2019 | $ (640) | $ (640) | $ 1 | $ 528,272 | $ (155,947) | $ 172,265 | $ (1,096) | $ 543,495 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Issuance of common stock under employee plans, net (in shares) | 315,404 | |||||||
Issuance of common stock under employee plans, net | (5,162) | (5,162) | ||||||
Stock-based compensation | 20,195 | 20,195 | ||||||
Net income | 4,074 | 4,074 | ||||||
Foreign currency translation adjustments | (2,372) | (2,372) | ||||||
Ending balance (in shares) at Mar. 31, 2020 | 59,813,163 | 20,220,227 | ||||||
Ending balance at Mar. 31, 2020 | $ 1 | 543,305 | $ (155,947) | 175,699 | (3,468) | 559,590 | ||
Beginning balance (in shares) at Dec. 31, 2020 | 63,766,555 | 20,220,227 | ||||||
Beginning balance at Dec. 31, 2020 | $ 1 | 962,159 | $ (155,947) | 169,901 | 141 | 976,255 | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Issuance of common stock under employee plans, net (in shares) | 906,536 | |||||||
Issuance of common stock under employee plans, net | (7,045) | (7,045) | ||||||
Stock-based compensation | 89,610 | 89,610 | ||||||
Net income | (47,917) | (47,917) | ||||||
Foreign currency translation adjustments | 1 | 1 | ||||||
Ending balance (in shares) at Mar. 31, 2021 | 64,673,091 | 20,220,227 | ||||||
Ending balance at Mar. 31, 2021 | $ 1 | $ 1,044,724 | $ (155,947) | $ 121,984 | $ 142 | $ 1,010,904 |
Unaudited Condensed Consolida_3
Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Cash flows from operating activities: | ||
Net income (loss) | $ (47,917) | $ 4,074 |
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||
Depreciation and amortization | 4,291 | 2,881 |
Loss on disposal and abandonment of intangible assets | 11 | 13 |
Loss on disposal and impairment of property and equipment, net | 45 | 517 |
Stock-based compensation | 89,610 | 20,195 |
Deferred income taxes | (598) | (1,548) |
Unrecognized tax benefits | 194 | 341 |
Other noncash | 2,615 | 1,156 |
Provision for expected credit losses | (335) | 902 |
Change in assets and liabilities: | ||
Accounts and notes receivable and contract assets | 31,298 | (9,700) |
Inventory | 520 | (8,630) |
Prepaid expenses and other assets | (6,952) | 2,277 |
Accounts payable, accrued and other liabilities | (18,062) | (3,562) |
Deferred revenue | 6,219 | 4,499 |
Net cash provided by operating activities | 60,939 | 13,415 |
Cash flows from investing activities: | ||
Purchases of investments | (155,825) | (99,512) |
Proceeds from call / maturity of investments | 132,254 | 84,315 |
Purchases of property and equipment | (10,521) | (2,209) |
Proceeds from disposal of property and equipment | 10 | 78 |
Purchases of intangible assets | (41) | (45) |
Strategic Investments | (20,000) | (4,700) |
Net cash used in investing activities | (54,123) | (22,073) |
Cash flows from financing activities: | ||
Proceeds from options exercised | 0 | 28 |
Income and payroll tax payments for net-settled stock awards | (7,045) | (5,190) |
Net cash used in financing activities | (7,045) | (5,162) |
Effect of exchange rate changes on cash and cash equivalents | (392) | (1,890) |
Net decrease in cash and cash equivalents | (621) | (15,710) |
Cash and cash equivalents and restricted cash, beginning of period | 155,551 | 172,355 |
Cash and cash equivalents and restricted cash, end of period | $ 154,930 | $ 156,645 |
Unaudited Condensed Consolida_4
Unaudited Condensed Consolidated Statements of Cash Flows - Supplemental - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Supplemental disclosures: | ||
Cash and cash equivalents | $ 154,822 | $ 156,540 |
Restricted cash (Note 1) | 108 | 105 |
Total cash, cash equivalents and restricted cash shown in the statements of cash flows | 154,930 | 156,645 |
Cash paid for income taxes, net of refunds | 4,152 | 3,863 |
Non-cash transactions | ||
Property and equipment purchases in accounts payable and accrued liabilities | 517 | 617 |
Investment purchases in accounts payable, net | $ 0 | $ 13,451 |
Organization and Summary of Sig
Organization and Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Summary of Significant Accounting Policies | 1. Organization and Summary of Significant Accounting Policies Axon Enterprise, Inc. (“Axon,” the “Company,” "we," or "us") is a market-leading provider of law enforcement technology solutions. Our core mission is to protect life. We fulfill that mission through developing hardware and software products that advance the long term objectives of a) obsoleting the bullet, b) reducing social conflict, and c) enabling a fair and effective justice system. Our headquarters in Scottsdale, Arizona houses our executive management, sales, marketing, certain engineering, manufacturing, finance and other administrative support functions. Our global software hub is located in Seattle, Washington, and we also have subsidiaries and / or offices located in Australia, Canada, Finland, Germany, Hong Kong, India, Italy, the Netherlands, the United Kingdom, and Vietnam. The accompanying unaudited condensed consolidated financial statements include the accounts of Axon Enterprise, Inc. and our wholly owned subsidiaries. All material intercompany accounts, transactions, and profits have been eliminated. Basis of Presentation and Use of Estimates These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the SEC. Certain information related to our organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in our annual consolidated financial statements for the year ended December 31, 2020, as filed on Form 10-K, with the exception of our adoption of certain accounting pronouncements which we describe below. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments, consisting only of normal recurring adjustments, necessary to fairly state our financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with our Form 10-K for the year ended December 31, 2020. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the full year (or any other period). Significant estimates and assumptions in these unaudited condensed consolidated financial statements include: ● product warranty reserves, ● inventory valuation, ● revenue recognition, ● reserve for expected credit loss, ● valuation of goodwill, intangible and long-lived assets, ● recognition, measurement and valuation of current and deferred income taxes, ● stock-based compensation, and ● recognition and measurement of contingencies and accrued litigation expense. Actual results could differ materially from those estimates. Segment Information Our operations are comprised of two reportable segments: the manufacture and sale of conducted electrical devices ("CEDs"), batteries, accessories, extended warranties and other products and services (the “TASER” segment); and the development, manufacture, and sale of software and sensors, which includes the sale of devices, wearables, applications, cloud and mobile products, and services (collectively, the “Software and Sensors” segment). In both segments, we report sales of products and services. Service revenue in both segments includes sales related to Axon Evidence. In the Software and Sensors segment, service revenue also includes other recurring cloud-hosted software revenue and related professional services. Collectively, this revenue is sometimes referred to as "Axon Cloud revenue." Reportable segments are determined based on discrete financial information reviewed by our Chief Executive Officer who is our chief operating decision maker ("CODM"). We organize and review operations based on products and services, and currently there are no operating segments that are aggregated. We perform an analysis of our reportable segments at least annually. Additional information related to our business segments is summarized in Note 13. Geographic Information and Major Customers / Suppliers For the three months ended March 31, 2021, no individual country outside the U.S. represented more than 10% of total net sales. Individual sales transactions in the international market are generally larger and occur more intermittently than in the domestic market due to the profile of our customers. For the three months ended March 31, 2021, no customer represented more than 10% of total net sales. At March 31, 2021 and December 31, 2020, no customer represented more than 10% of the aggregate balance of accounts and notes receivable and contract assets. We currently purchase both off the shelf and custom components, including, but not limited to, finished circuit boards, injection-molded plastic components, small machined parts, custom cartridge components, electronic components, and off the shelf sub-assemblies from suppliers located in the U.S., Canada, China, Israel, Republic of Korea, Mexico, Sri Lanka, and Taiwan. Although we currently obtain many of these components from single source suppliers, we own the injection molded component tooling, most of the designs, and the test fixtures used in their production for all custom components. As a result, we believe we could obtain alternative suppliers in most cases without incurring significant production delays. We also strategically hold safety stock levels on custom components to further reduce this risk. For off the shelf components, we believe that in most cases there are readily available alternative suppliers who can consistently meet our needs for these components. We acquire most of our components on a purchase order basis and do not have any significant long-term contracts with component suppliers. Income per Common Share Basic income per common share is computed by dividing net income by the weighted average number of common shares outstanding during the periods presented. Diluted income per share reflects the potential dilution from outstanding stock options and unvested restricted stock units. The calculation of the weighted average number of shares outstanding and earnings per share are as follows (in thousands except per share data): Three Months Ended March 31, 2021 2020 Numerator for basic and diluted earnings per share: Net income (loss) $ (47,917) $ 4,074 Denominator: Weighted average shares outstanding 64,036 59,609 Dilutive effect of stock-based awards — 785 Diluted weighted average shares outstanding 64,036 60,394 Anti-dilutive stock-based awards excluded 12,234 12,161 Net income (loss) per common share: Basic $ (0.75) $ 0.07 Diluted $ (0.75) $ 0.07 Standard Warranties We warranty our CEDs, Axon cameras and certain related accessories from manufacturing defects on a limited basis for a period of one year after purchase and, thereafter, will repair or replace any defective unit for a fee. Estimated costs for the standard warranty are charged to cost of products sold when revenue is recorded for the related product. Future warranty costs are estimated based on historical data related to warranty claims and this rate is applied to current product sales. Historically, reserve amounts have been increased if management becomes aware of a component failure or other issue that could result in larger than anticipated warranty claims from customers. The warranty reserve is reviewed quarterly to verify that it sufficiently reflects the remaining warranty obligations based on the anticipated expenditures over the balance of the warranty obligation period, and adjustments are made when actual warranty claim experience differs from estimates. The warranty reserve is included in accrued liabilities on the accompanying condensed consolidated balance sheets. Changes in our estimated product warranty liabilities were as follows (in thousands): Three Months Ended March 31, 2021 2020 Balance, beginning of period $ 769 $ 1,476 Utilization of reserve (231) (171) Warranty expense (benefit) 406 (85) Balance, end of period $ 944 $ 1,220 Fair Value Measurements and Financial Instruments We use the fair value framework that prioritizes the inputs to valuation techniques for measuring financial assets and liabilities measured on a recurring basis and for non-financial assets and liabilities when these items are re-measured. Fair value is considered to be the exchange price in an orderly transaction between market participants, to sell an asset or transfer a liability at the measurement date. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. We categorize each of our fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: ● Level 1 – Valuation techniques in which all significant inputs are unadjusted quoted prices from active markets for assets or liabilities that are identical to the assets or liabilities being measured. ● Level 2 – Valuation techniques in which significant inputs include quoted prices from active markets for assets or liabilities that are similar to the assets or liabilities being measured and/or quoted prices for assets or liabilities that are identical or similar to the assets or liabilities being measured from markets that are not active. Also, model-derived valuations in which all significant inputs and significant value drivers are observable in active markets are Level 2 valuation techniques. ● Level 3 – Valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Unobservable inputs are valuation technique inputs that reflect our own assumptions about inputs that market participants would use in pricing an asset or liability. We have cash equivalents and investments, which at March 31, 2021 and December 31, 2020 were comprised of money market funds, certificates of deposit, commercial paper, corporate bonds, municipal bonds, U.S. Government agency bonds, U.S. Treasury bills, and U.S. Treasury inflation-protected securities. Also included in cash equivalents and investments at December 31, 2020 were U.S. Treasury repurchase agreements. See additional disclosure regarding the fair value of our cash equivalents and investments in Note 3. Included in the balance of other assets as of March 31, 2021 and December 31, 2020 was $4.8 million and $4.7 million, respectively, related to corporate-owned life insurance policies which are used to fund our deferred compensation plan. We determine the fair value of insurance contracts by obtaining the cash surrender value of the contracts from the issuer, a Level 2 valuation technique. We have strategic investments in three unconsolidated affiliates, which are included within other assets. The estimated fair value of the investments was determined based on Level 3 inputs. As of March 31, 2021, management estimated that the fair value of the investments equaled the carrying value. Our financial instruments also include accounts and notes receivable, accounts payable and accrued liabilities. Due to the short-term nature of these instruments, their fair values approximate their carrying values on the balance sheet. Restricted Cash Restricted cash balances as of March 31, 2021 and December 31, 2020 included $0.1 million primarily related to funds held in an international bank account for a country in which we are required to maintain a minimum balance to operate. Approximately half of the balance was included in prepaid expenses and other current assets on our condensed consolidated balance sheets, with the remainder included in other assets. Valuation of Goodwill, Intangibles and Long-lived Assets We evaluate whether events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets, excluding goodwill and intangible assets with indefinite useful lives, may warrant revision or that the remaining balance of these assets may not be recoverable. Such circumstances could include, but are not limited to, a change in the product mix, a change in the way products are created, produced or delivered, or a significant change in the way products are branded and marketed. In performing the review for recoverability, we estimate the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. The amount of the impairment loss, if impairment exists, is calculated based on the excess of the carrying amounts of the assets over their estimated fair value computed using discounted cash flows. We do not amortize goodwill and intangible assets with indefinite useful lives; rather such assets are required to be tested for impairment at least annually or sooner whenever events or changes in circumstances indicate that the assets may be impaired. We perform our annual goodwill and intangible asset impairment tests in the fourth quarter of each year. Recently Issued Accounting Guidance Recently Adopted Accounting Pronouncements In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12, Simplifying the Accounting for Income Taxes. Adoption of this ASU on January 1, 2021 did not have a material impact on our consolidated financial statements. In January 2020, the FASB issued ASU No. 2020-01, Investments – Equity Securities (Topic 321), Investments – Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) – Clarifying the Interactions Between Topic 321, Topic 323, and Topic 815 (a Consensus of the Emerging Issues Task Force). The guidance clarifies the interaction between ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities and the ASU on equity method investments. ASU 2016-01 provides companies with an alternative to measure certain equity securities without a readily determinable fair value at cost, minus impairment, if any, unless an observable transaction for an identical or similar security occurs. ASU 2020-01 clarifies that for purposes of applying the Topic 321 measurement alternative, an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting under Topic 323, immediately before applying or upon discontinuing the equity method. In addition, the new ASU provides direction that a company should not consider whether the underlying securities would be accounted for under the equity method or the fair value option when it is determining the accounting for certain forward contracts and purchased options, upon either settlement or exercise. Adoption of this ASU on January 1, 2021 did not have a material impact on our consolidated financial statements. Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications are not material and had no effect on the reported results of operations. |
Revenues
Revenues | 3 Months Ended |
Mar. 31, 2021 | |
Revenue from Contract with Customer [Abstract] | |
Revenues | 2. Revenues Nature of Products and Services The following tables present our revenues by primary product and service offering (in thousands): Three Months Ended March 31, 2021 Three Months Ended March 31, 2020 Software and Software and TASER Sensors Total TASER Sensors Total TASER 7 $ 33,991 $ — $ 33,991 $ 15,326 $ — $ 15,326 TASER X26P 9,963 — 9,963 11,061 — 11,061 TASER X2 12,778 — 12,778 14,075 — 14,075 TASER Pulse 2,205 — 2,205 1,200 — 1,200 Cartridges 30,418 — 30,418 26,625 — 26,625 Axon Body — 19,756 19,756 — 12,823 12,823 Axon Flex — 905 905 — 1,183 1,183 Axon Fleet — 3,763 3,763 — 4,775 4,775 Axon Dock — 6,920 6,920 — 4,951 4,951 Axon Evidence and cloud services 1,396 52,294 53,690 498 39,154 39,652 Extended warranties 5,646 7,500 13,146 4,977 5,458 10,435 Other 2,602 4,882 7,484 2,133 2,923 5,056 Total $ 98,999 $ 96,020 $ 195,019 $ 75,895 $ 71,267 $ 147,162 The following table presents our revenues disaggregated by geography (in thousands): Three Months Ended March 31, 2021 2020 United States $ 160,386 82 % $ 117,463 80 % Other countries 34,633 18 29,699 20 Total $ 195,019 100 % $ 147,162 100 % Contract Balances The following table presents our contract assets, contract liabilities and certain information related to these balances as of and for the three months ended March 31, 2021 (in thousands): March 31, 2021 Contract assets, net $ 98,813 Contract liabilities (deferred revenue) 281,193 Revenue recognized in the period from: Amounts included in contract liabilities at the beginning of the period 63,871 Contract liabilities (deferred revenue) consisted of the following (in thousands): March 31, 2021 December 31, 2020 Current Long-Term Total Current Long-Term Total Warranty: TASER $ 10,501 $ 16,486 $ 26,987 $ 11,635 $ 16,953 $ 28,588 Software and Sensors 14,432 5,322 19,754 13,926 5,025 18,951 24,933 21,808 46,741 25,561 21,978 47,539 Hardware: TASER 16,040 15,024 31,064 16,314 14,304 30,618 Software and Sensors 23,723 51,265 74,988 25,181 50,981 76,162 39,763 66,289 106,052 41,495 65,285 106,780 Services: TASER 969 1,997 2,966 996 1,554 2,550 Software and Sensors 99,421 26,013 125,434 95,907 22,405 118,312 100,390 28,010 128,400 96,903 23,959 120,862 Total $ 165,086 $ 116,107 $ 281,193 $ 163,959 $ 111,222 $ 275,181 March 31, 2021 December 31, 2020 Current Long-Term Total Current Long-Term Total TASER $ 27,510 $ 33,507 $ 61,017 $ 28,945 $ 32,811 $ 61,756 Software and Sensors 137,576 82,600 220,176 135,014 78,411 213,425 Total $ 165,086 $ 116,107 $ 281,193 $ 163,959 $ 111,222 $ 275,181 Remaining Performance Obligations As of March 31, 2021, we had approximately $1.79 billion of remaining performance obligations, which included both recognized contract liabilities as well as amounts that will be invoiced and recognized in future periods. The remaining performance obligations are limited only to arrangements that meet the definition of a contract under Topic 606 as of March 31, 2021. We expect to recognize between 20% - 25% of this balance over the next twelve months, and generally expect the remainder to be recognized over the following five |
Cash, Cash Equivalents and Inve
Cash, Cash Equivalents and Investments | 3 Months Ended |
Mar. 31, 2021 | |
Cash and Cash Equivalents [Abstract] | |
Cash, Cash Equivalents and Investments | 3. Cash, Cash Equivalents and Investments The following tables summarize our cash, cash equivalents, and held-to-maturity investments at March 31, 2021 and December 31, 2020 (in thousands): As of March 31, 2021 Gross Gross Cash and Amortized Unrealized Unrealized Cash Short-Term Long-Term Cost Gains Losses Fair Value Equivalents Investments Investments Cash $ 137,003 $ — $ — $ 137,003 $ 137,003 $ — $ — Level 1: Money market funds 16,819 — — 16,819 16,819 — — Agency bonds 73,996 94 — 74,090 — 45,995 28,001 Treasury bills 104,184 13 — 104,197 — 104,184 — Subtotal 194,999 107 — 195,106 16,819 150,179 28,001 Level 2: State and municipal obligations 83,086 12 (30) 83,068 — 74,295 8,791 Certificates of deposit 500 — — 500 — 500 — Corporate bonds 186,406 140 (81) 186,465 1,002 143,712 41,692 Treasury inflation-protected securities 3,310 7 — 3,317 — 3,310 — Commercial paper 68,961 — — 68,961 — 68,961 — Subtotal 342,263 159 (111) 342,311 1,002 290,778 50,483 Total $ 674,265 $ 266 $ (111) $ 674,420 $ 154,824 $ 440,957 $ 78,484 Because we do not have any history of losses for our held-to-maturity investments, o As of December 31, 2020 Gross Gross Cash and Amortized Unrealized Unrealized Cash Short-Term Long-Term Cost Gains Losses Fair Value Equivalents Investments Investments Cash $ 116,107 $ — $ — $ 116,107 $ 116,107 $ — $ — Level 1: Money market funds 23,611 — — 23,611 23,611 — — Agency bonds 63,794 122 — 63,916 — 23,794 40,000 Treasury Bills 96,384 6 — 96,390 96,384 Subtotal 183,789 128 — 183,917 23,611 120,178 40,000 Level 2: State and municipal obligations 77,130 25 (28) 77,127 — 66,519 10,611 Certificates of deposit 500 — — 500 — 500 — Corporate bonds 212,825 232 (100) 212,957 2,525 170,205 40,095 U.S. Treasury repurchase agreements 13,200 — — 13,200 13,200 — — Treasury inflation-protected securities 3,291 16 — 3,307 — 3,291 Commercial paper 45,974 — — 45,974 45,974 — Subtotal 352,920 273 (128) 353,065 15,725 286,489 50,706 Total $ 652,816 $ 401 $ (128) $ 653,089 $ 155,443 $ 406,667 $ 90,706 |
Expected Credit Losses
Expected Credit Losses | 3 Months Ended |
Mar. 31, 2021 | |
Expected Credit Losses | |
Expected Credit Losses | 4. Expected Credit Losses We are exposed to credit losses primarily through sales of products and services. Our expected loss allowance methodology for accounts receivable, notes receivable, and contract assets is developed using historical collection experience, published or estimated credit default rates for entities that represent our customer base, current and future economic and market conditions and a review of the current status of customers' trade accounts receivables. Additionally, specific allowance amounts are established to record the appropriate provision for customers that have a higher probability of default. Our monitoring activities include account reconciliation, dispute resolution, payment confirmation, consideration of customers' financial condition and macroeconomic conditions. Balances are written off when determined to be uncollectible. We considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and recorded an additional reserve for credit loss of approximately $0.8 million as of March 31, 2021. We review receivables for U.S. and international customers separately to better reflect different published credit default rates and economic and market conditions. The following table provides a roll-forward of the allowance for expected credit losses that is deducted from the amortized cost basis of accounts receivable, notes receivable, and contract assets to present the net amount expected to be collected (in thousands): Three Months Ended March 31, 2021 United States Other countries Total Balance, beginning of period $ 2,902 $ 474 $ 3,376 Provision for expected credit losses (99) (205) (304) Amounts written off charged against the allowance (39) - (39) Other, including foreign currency translation 134 1 135 Balance, end of period $ 2,898 $ 270 $ 3,168 March 31, December 31, 2021 2020 Accounts receivable and notes receivable, current $ 1,796 $ 2,105 Contract assets, net 991 794 Long-term notes receivable, net of current portion 381 477 Total allowance for expected credit losses on customer receivables $ 3,168 $ 3,376 |
Inventory
Inventory | 3 Months Ended |
Mar. 31, 2021 | |
Inventory Disclosure [Abstract] | |
Inventory | 5. Inventory Inventories are stated at the lower of cost and net realizable value. Cost is determined using the weighted average cost of raw materials, which approximates the first-in, first-out (“FIFO”) method and includes allocations of manufacturing labor and overhead. Provisions are made to reduce excess, obsolete or slow-moving inventories to their net realizable value. Inventory consisted of the following at March 31, 2021 and December 31, 2020 (in thousands): March 31, 2021 December 31, 2020 Raw materials $ 33,918 $ 39,194 Finished goods 55,739 50,764 Total inventory $ 89,657 $ 89,958 |
Other Long-Term Assets
Other Long-Term Assets | 3 Months Ended |
Mar. 31, 2021 | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |
Other Long-Term Assets | 6. Other Long-Term Assets Other long-term assets consisted of the following at March 31, 2021 and December 31, 2020 (in thousands): March 31, 2021 December 31, 2020 Cash surrender value of corporate-owned life insurance policies $ 4,806 $ 4,654 Deferred commissions (1) 32,337 32,455 Restricted cash 59 62 Operating lease assets 23,168 22,308 Strategic investments (2) 29,500 9,500 Warrants for strategic investment (3) 2,211 2,211 Prepaid expenses, deposits and other 10,839 8,727 Total other long-term assets $ 102,920 $ 79,917 (1) Represents the incremental costs of obtaining contracts with customers, which consist primarily of sales commissions. These costs are ascribed to or allocated to the underlying performance obligations in the contracts and amortized consistent with the recognition timing of the revenue for the underlying performance obligations. (2) Strategic investments include investments in non-public technology-driven companies. We account for strategic investments under the ASC 321 measurement alternative for equity securities without readily determinable fair values, as there are no quoted market prices for the investment. The investments are measured at cost less impairment, adjusted for observable price changes and is assessed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. As of March 31, 2021, no impairment was recorded for the investments. We did not recognize any adjustments to the recorded cost bases during the three months ended March 31, 2021. We have recognized an increase of $2.4 million in the cost bases since our initial investment. During the three months ended March 31, 2021, we made a $20.0 million minority investment in RapidSOS, Inc. (3) In conjunction with our strategic investment in and commercial partnership with Flock Group Inc., we have the ability to commit additional capital over time through warrants where the exercisability and exercise prices are conditional on the achievement of certain partnership performance metrics. The amount reflected in other assets represents the fair value of the preferred stock warrants, as adjusted for observable price changes of $0.4 million during the quarter ended December 31, 2020. |
Accrued Liabilities
Accrued Liabilities | 3 Months Ended |
Mar. 31, 2021 | |
Payables and Accruals [Abstract] | |
Accrued Liabilities | 7. Accrued Liabilities Accrued liabilities consisted of the following at March 31, 2021 and December 31, 2020 (in thousands): March 31, 2021 December 31, 2020 Accrued salaries, benefits and bonus $ 21,880 $ 36,892 Accrued professional, consulting and lobbying fees 1,318 3,055 Accrued warranty expense 944 769 Accrued income and other taxes 2,482 3,848 Accrued inventory in transit 4,696 4,597 Other accrued expenses 9,777 10,682 Accrued liabilities $ 41,097 $ 59,843 |
Income Taxes
Income Taxes | 3 Months Ended |
Mar. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | 8. Income Taxes We file income tax returns for federal purposes and in many states, as well as in multiple foreign jurisdictions. Our tax filings remain subject to examination by applicable tax authorities for a certain length of time, generally three to four years, following the tax year to which these filings relate. During the second quarter of 2020 we began an audit with the State of California for our fiscal year 2016 and 2017 state tax returns, which is currently in the final closing phase. During the first quarter of 2021, we were notified that an audit with the State of Illinois for our fiscal year 2018 will commence during the second quarter of 2021. Additionally, we have been notified that an audit may commence for Axon Public Safety Southeast Asia LLC, our entity in Vietnam. The tax period has not yet been defined. On March 11, 2021, the U.S. federal government enacted the American Rescue Plan Act. This act is an emergency economic stimulus package in response to the COVID-19 pandemic, which, among other things, contains numerous income tax provisions. We are continuing to evaluate the implications of the American Rescue Plan Act, but its impact on the financial statements and related disclosures is not expected to be material. Deferred Tax Assets Net deferred income tax assets at March 31, 2021, primarily include R&D tax credits, stock-based compensation expense, deferred revenue, accruals and reserves, and net operating losses, partially offset by accelerated depreciation expense and valuation allowance reserve. Our total net deferred tax assets at March 31, 2021 were $45.7 million. In preparing our condensed consolidated financial statements, management assesses the likelihood that its deferred tax assets will be realized from future taxable income. In evaluating our ability to recover our deferred income tax assets, management considers all available positive and negative evidence, including our operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction by jurisdiction basis. A valuation allowance is established if it is determined that it is more likely than not that some portion or all of the net deferred tax assets will not be realized. Management exercises significant judgment in determining our provisions for income taxes, our deferred tax assets and liabilities, and our future taxable income for purposes of assessing our ability to utilize any future tax benefit from our deferred tax assets. As of March 31, 2021, we continue to demonstrate three-year cumulative pre-tax income in the U.S. federal and state tax jurisdictions; however, we have Arizona R&D tax credits expiring unutilized each year. Therefore, management has concluded that it is more likely than not that our Arizona R&D deferred tax asset will not be realized. In Australia, we have determined that sufficient deferred tax liabilities will reverse in order to realize all assets except one long-lived intangible where there is not an expectation that the asset may be realized. Therefore, we have recorded a partial valuation allowance for Australia. We complete R&D tax credit studies for each year that an R&D tax credit is claimed for federal, Arizona, and California income tax purposes. Management has made the determination that it is more likely than not that the full benefit of the R&D tax credit will not be sustained on examination and recorded a liability for unrecognized tax benefits of $7.2 million as of March 31, 2021. Should the unrecognized benefit of $7.2 million be recognized, our effective tax rate would be favorably impacted. Approximately $2.7 million of the unrecognized tax benefit associated with R&D credits has been netted against the R&D deferred tax asset. Effective Tax Rate Our overall effective tax rate for the three months ended March 31, 2021, after discrete period adjustments, was 3.5%. Before discrete adjustments, the tax rate was (20.5%), which differs from the federal statutory rate, primarily due to the impact of the executive compensation limitation under Internal Revenue Code ("IRC") Section 162(m), partially offset by R&D tax credits, on a projected pre-tax loss for the year. The effective tax rate was favorably impacted by an $11.7 million discrete tax benefit primarily associated with windfalls related to stock-based compensation for restricted stock units (“RSUs”) or performance stock units (“PSUs”) that vested during the three months ended March 31, 2021. |
Stockholders' Equity
Stockholders' Equity | 3 Months Ended |
Mar. 31, 2021 | |
Equity [Abstract] | |
Stockholders' Equity | 9. Stockholders’ Equity Performance-based stock awards We have issued performance-based stock options and performance-based RSUs, the vesting of which is generally contingent upon the achievement of certain performance criteria related to our operating performance, as well as successful and timely development and market acceptance of future product introductions. In addition, certain of the performance RSUs have additional service requirements subsequent to the achievement of the performance criteria. Compensation expense is recognized over the requisite service period, which is defined as the longest explicit, implicit or derived service period based on management’s estimate of the probability of the performance criteria being satisfied, adjusted at each balance sheet date. For both service-based and performance-based RSUs, we account for forfeitures as they occur as a reduction to stock-based compensation expense and additional paid-in-capital. For performance-based options with a vesting schedule based entirely on the attainment of both performance and market conditions, stock-based compensation expense is recognized for each pair of performance and market conditions over the longer of the expected achievement period of the performance and market conditions, beginning at the point in time that the relevant performance condition is considered probable of achievement. The fair value of such awards is estimated on the grant date using Monte Carlo simulations. CEO Performance Award On May 24, 2018, our stockholders approved the Board of Directors’ grant of 6,365,856 stock option awards to Patrick W. Smith, our CEO (the “CEO Performance Award”). The CEO Performance Award consists of 12 vesting tranches with a vesting schedule based entirely on the attainment of both operational goals (performance conditions) and market capitalization goals (market conditions), assuming continued employment either as the CEO or as both Executive Chairman and Chief Product Officer and service through each attainment date. Each of the 12 vesting tranches of the CEO Performance Award have a 10-year Eight Separate Adjusted EBITDA (CEO Eight Separate Revenue Goals (1) Performance Award) Goals (in thousands) (in thousands) Goal #1, $710,058 Goal #9, $125,000 Goal #2, $860,058 Goal #10, $155,000 Goal #3, $1,010,058 Goal #11, $175,000 Goal #4, $1,210,058 Goal #12, $190,000 Goal #5, $1,410,058 Goal #13, $200,000 Goal #6, $1,610,058 Goal #14, $210,000 Goal #7, $1,810,058 Goal #15, $220,000 Goal #8, $2,010,058 Goal #16, $230,000 (1) In connection with the business acquisition that was completed during the three months ended June 30, 2018, the revenue goals were adjusted for the acquiree’s Target Revenue, as defined in the CEO Performance Award agreement. As of March 31, 2021, the following operational goals were achieved, with vesting of the related tranche pending certification by the Compensation Committee: ● Adjusted EBITDA (CEO Performance Award) of $155.0 million ● Total revenue of $710.1 million As of March 31, 2021, the following operational goals were considered probable of achievement: ● Total revenue of $860.1 million, $1,010.1 million, and $1,210.1 million; and ● Adjusted EBITDA (CEO Performance Award) of $175.0 million, $190.0 million, $200.0 million, $210.0 million, $220.0 million, and $230.0 million. The operational goal of $125.0 million Adjusted EBITDA (CEO Performance Award) was previously achieved and the related options vested in March 2021. Stock-based compensation expense associated with the CEO Performance Award is recognized over the requisite service period, which is defined as the longest explicit, implicit or derived service period, based on management’s estimate of the probability and timing of the performance criteria being satisfied, adjusted at each balance sheet date. Expense recognition begins at the point in time when the relevant operational goal is considered probable of being met. The probability of attaining an operational goal and the expected attainment date for meeting a probable operational goal are based on a subjective assessment of our forward-looking financial projections, taking into consideration statistical analysis. The statistical model and the assessment that determine the estimated attainment dates are subject to a number of estimated inputs, including expected volatility rates, management’s forward-looking financial projections, in particular for operational goals that are anticipated to be attained in the near future, and adjustment of other estimates based on the passage of time. The first seven market capitalization goals have been achieved as of March 31, 2021. As of March 31, 2021, 0.5 million stock options have vested. As all twelve operational goals are considered probable of achievement, we recorded stock-based compensation expense of $132.4 million related to the CEO Performance Award from the Grant Date through March 31, 2021. The number of stock options that would vest related to the remaining unvested tranches is approximately 5.8 million shares. As of March 31, 2021, we had $113.6 million of total unrecognized stock-based compensation expense for the performance goals that were considered probable of achievement, which will be recognized over a weighted-average period of 3.17 years. eXponential Stock Performance Plan On February 12, 2019, our shareholders approved the 2019 Stock Incentive Plan (the “2019 Plan”), which was adopted by the Board of Directors to reserve a sufficient number of shares to facilitate our eXponential Stock Performance Plan (“XSPP”) and grants of eXponential Stock Units (“XSUs”) under the plan. Initial awards under the plan were granted in January 2019, with additional employee awards granted since that date. During the three months ended March 31, 2021, and 2020 we granted an additional ten thousand and forty three The XSUs are grants of RSUs, each with a term of approximately nine years, that vest in 12 equal tranches. Each of the 12 tranches will vest upon certification by the Compensation Committee of the Board of Directors that both (i) the market capitalization goal for such tranche, which begins at $2.5 billion for the first tranche and increases by increments of $1.0 billion thereafter, and (ii) any one of eight operational goals focused on revenue or eight operational goals focused on Adjusted EBITDA (CEO Performance Award) have been met for the previous four consecutive fiscal quarters. The XSPP contains an anti-dilution provision incorporated into the plan based on shareholder feedback, which affects the calculation of the market capitalization goals in the plan. The plan defines a maximum number of shares outstanding that may be used in the calculation of the market capitalization goals (the “XSU Maximum”). If the actual number of shares outstanding exceeds the XSU Maximum guardrail, then the lower pre-defined number of shares in the XSU Maximum, rather than the higher actual number of shares outstanding, is used to calculate market capitalization for the determination of the market capitalization goals in the XSPP, which, together with the operational goals, determines whether XSUs vest for participating employees. The XSU Maximum is defined as the actual number of shares outstanding on the original XSU grant date of January 2, 2019, increased by a 3% annual rate over the term of the XSPP and by shares issued upon the exercise of CEO Performance Award options. The XSU Maximum is also adjusted for acquisitions, spin-offs or other changes in the number of outstanding shares of common stock, if such changes have a corresponding adjustment on the market capitalization goals. New shares issued for any other reasons, including shares issued upon vesting of XSUs, RSUs, and Performance Stock Units (“PSUs”) as well as shares issued to raise capital through equity issuances or in other transactions, do not increase the XSU Maximum. The market capitalization and operational goals are identical to the CEO Performance Award, but a different number of shares is used to calculate the market capitalization goals if shares outstanding exceed the XSU Maximum. Additionally, because the grant date is different than that of the CEO Performance Award, the measurement period for market capitalization is not identical. As of March 31, 2021, actual shares outstanding exceeded the XSU Maximum as a result of the common stock offering completed in June 2020. Accordingly, market capitalization as calculated for the purposes of achieving additional goals uses the lower XSU Maximum share amount rather than actual shares outstanding. The first six market capitalization goals have been achieved as of March 31, 2021, and the seventh market capitalization goal was achieved in April 2021. The first XSU tranche vested in March 2021. As all twelve operational goals are considered probable of achievement, we recorded stock-based compensation expense of $94.8 million related to the XSU awards from their respective grant dates through March 31, 2021. The number of XSU awards that would vest related to the remaining eleven tranches is approximately 4.9 million shares. As of March 31, 2021, we had $96.7 million of total unrecognized stock-based compensation expense, which will be recognized over a weighted-average period of 3.00 years. Restricted Stock Units The following table summarizes RSU activity for the three months ended March 31, 2021 (number of units and aggregate intrinsic value in thousands): Number of Weighted Average Aggregate Units Grant-Date Fair Value Intrinsic Value Units outstanding, beginning of year 1,107 $ 76.10 Granted 57 152.58 Released (184) 47.57 Forfeited (25) 91.87 Units outstanding, end of period 955 85.76 $ 136,019 Aggregate intrinsic value represents our closing stock price on the last trading day of the period, which was $142.42 per share, multiplied by the number of RSUs outstanding. As of March 31, 2021, there was $64.3 million in unrecognized compensation costs related to RSUs under our stock plans for shares that are expected to vest. We expect to recognize the cost related to the RSUs over a weighted average period of 2.22 years. RSUs are released when vesting requirements are met. Certain RSUs that vested in the three months ended March 31, 2021 were net-share settled such that we withheld shares to cover the employees’ tax obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. Total shares withheld related to RSUs were less than 0.1 million and had a value of $6.9 million on their respective vesting dates as determined by the closing stock price on such dates. Payments for the employees’ tax obligations are reflected as a financing activity within the condensed consolidated statements of cash flows. We record a liability for the tax withholding to be paid by us as a reduction to additional paid-in capital. Performance Stock Units The following table summarizes PSU activity, inclusive of XSUs, for the three months ended March 31, 2021 (number of units and aggregate intrinsic value in thousands): Number of Weighted Average Aggregate Units Grant-Date Fair Value Intrinsic Value Units outstanding, beginning of year 5,618 $ 35.71 Granted 190 43.83 Released (765) 37.61 Forfeited (41) 34.70 Units outstanding, end of period 5,002 35.74 $ 712,357 Aggregate intrinsic value represents our closing stock price on the last trading day of the period, which was $142.42 per share, multiplied by the number of PSUs outstanding. As of March 31, 2021, there was $100.7 million in unrecognized compensation costs related to PSUs under our stock plans for shares that are expected to vest. We expect to recognize the cost related to the PSUs over a weighted average period of 2.98 years. PSUs are released when vesting requirements are met. As of March 31, 2021, the performance criteria had been met for approximately 0.9 million of the 5.0 million PSUs outstanding. On March 8, 2021, the Compensation Committee of our Board of Directors approved a one-time waiver of the holding period requirements for each XSPP participant who elected to receive XSUs in lieu of On-Target Earnings and is an Arizona resident. This waiver allows participants to sell a portion of their vested shares to satisfy income tax obligations pursuant to Arizona Proposition 208 which was passed in November 2020. Such one-time waiver applied only to 4% of the XSUs for the impacted participants which vested on March 8, 2021, which was approximately 13 thousand shares. We accounted for this change as a Type I modification under ASC 718 since there was no impact on attainment of the operational or market capitalization goals. We recognized additional stock-based compensation expense of $0.4 million for the three months ended March 31, 2021. Certain PSUs that vested in the three months ended March 31, 2021 were net-share settled such that we withheld shares to cover the employees’ tax obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. Total shares withheld related to PSUs were approximately two thousand and had a value of $0.1 million on their respective vesting dates as determined by the closing stock price on such dates. Payments for the employees’ tax obligations are reflected as a financing activity within the condensed consolidated statements of cash flows. We record a liability for the tax withholding to be paid by us as a reduction to additional paid-in capital. Stock Option Activity The following table summarizes stock option activity for the three months ended March 31, 2021 (number of units and aggregate intrinsic value in thousands): Weighted Weighted Average Number Average Remaining of Exercise Contractual Aggregate Options Price Life (years) Intrinsic Value Options outstanding, beginning of year 6,366 $ 28.58 Granted — — Exercised — — Expired / terminated — — Options outstanding, end of period 6,366 28.58 6.91 $ 724,689 Options exercisable, end of period 1,591 28.58 6.91 181,172 Aggregate intrinsic value represents the difference between the exercise price of the underlying stock option awards and the closing market price of our common stock of $142.42 on March 31, 2021. There were no options exercised for the three months ended March 31, 2021. The intrinsic value of options exercised for the three months ended March 31, 2020 was $0.3 million. As of March 31, 2021, total options outstanding included 4.8 million unvested performance-based stock options, which relate to the CEO Performance Award and are probable of achievement. Stock-based Compensation Expense The following table summarizes the composition of stock-based compensation expense for the three months ended March 31, 2021 and 2020 (in thousands): Three Months Ended March 31, 2021 2020 Cost of products sold and services delivered $ 1,489 $ 590 Sales, general and administrative expenses 71,015 14,970 Research and development expenses 17,106 4,635 Total stock-based compensation expense $ 89,610 $ 20,195 Stock Incentive Plan In February 2019, our shareholders approved the 2019 Plan authorizing an additional 6.0 million shares, plus remaining available shares under prior plans, for issuance under the new plan. Combined with the legacy stock incentive plans, there are 1.9 million shares available for grant as of March 31, 2021. Stock Repurchase Plan In February 2016, our Board of Directors authorized a stock repurchase program to acquire up to $50.0 million of our outstanding common stock subject to stock market conditions and corporate considerations. During the three months ended March 31, 2021 and 2020, no common shares were purchased under the program. As of March 31, 2021, $16.3 million remains available under the plan for future purchases. Any future purchases will be discretionary. |
Line of Credit
Line of Credit | 3 Months Ended |
Mar. 31, 2021 | |
Debt Disclosure [Abstract] | |
Line of Credit | 10. Line of Credit We have a $50.0 million unsecured revolving line of credit with a domestic bank, of which $20.0 million is available for letters of credit. The credit agreement matures on December 31, 2023 and has an accordion feature which allows for an increase in the total line of credit up to $100.0 million, subject to certain conditions, including the availability of additional bank commitments. At March 31, 2021 and December 31, 2020, there were no borrowings under the line. Under the terms of the line of credit, available borrowings are reduced by outstanding letters of credit. As of March 31, 2021, we had letters of credit outstanding of approximately $6.1 million under the facility and available borrowing of $43.9 million, excluding amounts available under the accordion feature. Advances under the line of credit bear interest at LIBOR plus 1.0 to 1.5% per year determined in accordance with a pricing grid based on our funded debt to earnings before interest, taxes, depreciation and amortization ("EBITDA") ratio. We are required to comply with a maximum funded debt to EBITDA ratio of no greater than 2.50 to 1.00 based upon a trailing four fiscal quarter period. At March 31, 2021, our funded debt to EBITDA ratio was 0.00 to 1.00. |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 11. Commitments and Contingencies Product Litigation As a manufacturer of weapons and other law enforcement tools used in high-risk field environments, we are often the subject of products liability litigation concerning the use of our products. We are currently named as a defendant in five lawsuits (one pending dismissal) in which the plaintiffs allege either wrongful death or personal injury in situations in which a TASER CED was used by law enforcement officers in connection with arrests or training. While the facts vary from case to case, these product liability claims typically allege defective product design, manufacturing, and/or failure to warn. They seek compensatory and sometimes punitive damages, often in unspecified amounts. We continue to aggressively defend all product litigation. As a general rule, it is our policy not to settle suspect injury or death cases. Exceptions are sometimes made where the settlement is strategically beneficial to us. Due to the confidential nature of our litigation strategy and the confidentiality agreements that are executed in the event of a settlement, we do not identify or comment on specific settlements by case or amount. Based on current information, we do not believe that the outcome of any such legal proceeding will have a material effect on our financial position, results of operations, or cash flows. We are self-insured for the first $5.0 million of any product claim made after 2014. No judgment or settlement has ever exceeded this amount in any products case. We continue to maintain product liability insurance coverage, including an insurance policy fronting arrangement, above our self-insured retention with various limits depending on the policy period. The litigation information in this note is current through the date of these financial statements. U.S. Federal Trade Commission Litigation The U.S. Federal Trade Commission (“FTC”) filed an enforcement action on January 3, 2020 regarding Axon’s May 2018 acquisition of Vievu LLC from Safariland LLC. The FTC alleges the merger was anticompetitive and adversely affected the body worn camera (“BWC”) and digital evidence management systems (“DEMS”) market for “large metropolitan police departments.” Fact and expert discovery is complete. On October 2, 2020, the Ninth Circuit stayed the administrative hearing set for October 13, 2020 pending decision on Axon’s appeal (see below). If ultimately successful, the FTC may require Axon to divest Vievu and other assets or take other remedial measures, any of which could be material to Axon. We are vigorously defending the matter. At this time, we cannot predict the eventual scope, duration, or outcome of the proceeding and accordingly we have not recorded any liability in the accompanying consolidated financial statements. Prior to the FTC’s enforcement action, Axon sued the FTC in federal court in the District of Arizona for declaratory and injunctive relief alleging the FTC’s structure and administrative processes violate Article II of the U.S. Constitution and our Fifth Amendment rights to due process and equal protection. On April 8, 2020, the district court dismissed the action, without prejudice, for lack of jurisdiction, requiring Axon to first bring its constitutional claims in the administrative case. The Ninth Circuit affirmed that ruling on January 28, 2021 (No. 20-15662) in a split 2-1 decision and has denied Axon’s petition for rehearing en banc. However, the Court did grant Axon’s motion to stay the appellate mandate pending the filing of its petition for certiorari with the U.S. Supreme Court. That petition must be filed by September 13, 2021. The FTC’s administrative case will remain stayed pending resolution of the Supreme Court proceedings. In parallel to these matters, we are evaluating strategic alternatives to litigation, which we might pursue if determined to be in the best interests of shareholders and customers. This could include a divestiture of the Vievu entity and/or related assets and the licensure of certain intellectual and other intangible property. While we continue to believe the acquisition of Vievu was lawful and a benefit to Vievu’s customers, the cost, risk and distraction of protracted litigation merit consideration of settlement if achievable on terms agreeable to the FTC and the company. General From time to time, we are notified that we may be a party to a lawsuit or that a claim is being made against us. It is our policy to not disclose the specifics of any claim or threatened lawsuit until the summons and complaint are actually served on us. After carefully assessing the claim, and assuming we determine that we are not at fault or we disagree with the damages or relief demanded, we vigorously defend any lawsuit filed against us. We record a liability when losses are deemed probable and reasonably estimable. When losses are deemed reasonably possible but not probable, we determine whether it is possible to provide an estimate of the amount of the loss or range of possible losses for the claim, if material for disclosure. In evaluating matters for accrual and disclosure purposes, we take into consideration factors such as our historical experience with matters of a similar nature, the specific facts and circumstances asserted, the likelihood of our prevailing, the availability of insurance, and the severity of any potential loss. We reevaluate and update accruals as matters progress over time. Based on our assessment of outstanding litigation and claims as of March 31, 2021, we have determined that it is not reasonably possible that these lawsuits will individually, or in the aggregate, materially affect our results of operations, financial condition or cash flows. However, the outcome of any litigation is inherently uncertain and there can be no assurance that any expense, liability or damages that may ultimately result from the resolution of these matters will be covered by our insurance or will not be in excess of amounts recognized or provided by insurance coverage and will not have a material adverse effect on our operating results, financial condition or cash flows. Off-Balance Sheet Arrangements Under certain circumstances, we use letters of credit and surety bonds to guarantee our performance under various contracts, principally in connection with the installation and integration of Axon cameras and related technologies. Certain of our letters of credit and surety bonds have stated expiration dates with others being released as the contractual performance terms are completed. At March 31, 2021, we had outstanding letters of credit of $6.1 million that are expected to expire in June 2021 and September 2021. We also had outstanding letters of credit and bank guarantees of $2.0 million that do not draw against our credit facility. The outstanding letters of credit are expected to expire in January 2022 and March 2022. Additionally, we had $21.5 million of outstanding surety bonds at March 31, 2021, $0.4 million expiring in 2021, $3.1 million expiring in 2022, $7.5 million expiring in 2023 and the remaining $10.5 million expiring in 2024. Subsequent Event On April 8, 2021, we entered into a Share Purchase Agreement with Cellebrite DI Ltd. ("Cellebrite") and Cellebrite’s shareholders, pursuant to which we have agreed to purchase, and Cellebrite has agreed to sell, an aggregate of 9,000,000 shares of common stock of Cellebrite, for a purchase price of $10.00 per share and an aggregate purchase price of $90,000,000 . This investment is being made in connection with Cellebrite’s business combination with TWC Tech Holdings II Corp. (“TWC Tech Holdings”), a publicly traded special purpose acquisition company, pursuant to the definitive business combination agreement and plan of merger (the “Business Combination”). The obligations to consummate the transactions contemplated by the Share Purchase Agreement are conditioned upon, among other things, customary closing conditions and the consummation of the Business Combination and other transactions contemplated by the plan of merger between Cellebrite and TWC Tech Holdings. |
Employee Benefit Plans
Employee Benefit Plans | 3 Months Ended |
Mar. 31, 2021 | |
Retirement Benefits [Abstract] | |
Employee Benefit Plans | 12. Employee Benefit Plans We have a defined contribution 401(k) plan for eligible employees, which is qualified under Sections 401(a) and 401(k) of the Internal Revenue Code of 1986, as amended. Employees are entitled to make tax-deferred contributions of up to the maximum amount allowed by law of their eligible compensation. We also have a non-qualified deferred compensation plan for certain executives, employees and non-employee directors through which participants may elect to postpone the receipt and taxation of a portion of their compensation, including stock-based compensation, received from us. The non-qualified deferred compensation plan allows eligible participants to defer up to 80% of their base salary and up to 100% of other types of compensation. The plan also allows for matching and discretionary employer contributions. Employee deferrals are deemed 100% vested upon contribution. Distributions from the plan are made upon retirement, death, separation of service, specified date or upon the occurrence of an unforeseeable emergency. Distributions can be paid in a variety of forms from lump sum to installments over a period of years. Participants in the plan are entitled to select from a wide variety of investments available under the plan and are allocated gains or losses based upon the performance of the investments selected by the participant. All gains or losses are allocated fully to plan participants and we do not guarantee a rate of return on deferred balances. Assets related to this plan consist of corporate-owned life insurance contracts and are included in other assets in the condensed consolidated balance sheets; see Note 6 for balances. Participants have no rights or claims with respect to any plan assets and any such assets are subject to the claims of our general creditors. Contributions to the plans are made by both the employee and us. Our contributions to the 401(k) plan are based on the level of employee contributions and are immediately vested. Future matching contributions to the plans are at our sole discretion. We also sponsor defined contribution plans in Australia, Canada, Finland, and the United Kingdom. Our matching contributions for all defined contribution plans were $2.1 million and $1.5 million for the three months ended March 31, 2021 and 2020, respectively. |
Segment Data
Segment Data | 3 Months Ended |
Mar. 31, 2021 | |
Segment Reporting [Abstract] | |
Segment Data | 13. Segment Data Our operations are comprised of two reportable segments: the manufacture and sale of CEDs, batteries, accessories, extended warranties and other products and services (the “TASER” segment); and the software and sensors business, which includes the sale of devices, wearables, applications, cloud and mobile products, and services (collectively, the “Software and Sensors” segment). In both segments, we report sales of products and services. Service revenue in both segments includes sales related to Axon Evidence. In the Software and Sensors segment, service revenue also includes other recurring cloud-hosted software revenue and related professional services. Collectively, this revenue is sometimes referred to as "Axon Cloud revenue." Our Chief Executive Officer, who is the CODM, is not provided asset information or sales, general, and administrative expense by segment. Information relative to our reportable segments was as follows (in thousands): Three Months Ended March 31, 2021 Three Months Ended March 31, 2020 Software and Software and TASER Sensors Total TASER Sensors Total Net sales from products $ 97,302 $ 43,584 $ 140,886 $ 75,175 $ 32,113 $ 107,288 Net sales from services 1,697 52,436 54,133 720 39,154 39,874 Net sales 98,999 96,020 195,019 75,895 71,267 147,162 Cost of product sales 32,945 25,671 58,616 30,248 18,636 48,884 Cost of service sales — 13,050 13,050 — 9,670 9,670 Cost of sales 32,945 38,721 71,666 30,248 28,306 58,554 Gross margin $ 66,054 $ 57,299 $ 123,353 $ 45,647 $ 42,961 $ 88,608 Research and development $ 9,243 $ 37,775 $ 47,018 $ 3,032 $ 23,349 $ 26,381 |
Organization and Summary of S_2
Organization and Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of Presentation and Use of Estimates | Basis of Presentation and Use of Estimates These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the SEC. Certain information related to our organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in our annual consolidated financial statements for the year ended December 31, 2020, as filed on Form 10-K, with the exception of our adoption of certain accounting pronouncements which we describe below. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments, consisting only of normal recurring adjustments, necessary to fairly state our financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with our Form 10-K for the year ended December 31, 2020. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the full year (or any other period). Significant estimates and assumptions in these unaudited condensed consolidated financial statements include: ● product warranty reserves, ● inventory valuation, ● revenue recognition, ● reserve for expected credit loss, ● valuation of goodwill, intangible and long-lived assets, ● recognition, measurement and valuation of current and deferred income taxes, ● stock-based compensation, and ● recognition and measurement of contingencies and accrued litigation expense. Actual results could differ materially from those estimates. |
Segment Information | Segment Information Our operations are comprised of two reportable segments: the manufacture and sale of conducted electrical devices ("CEDs"), batteries, accessories, extended warranties and other products and services (the “TASER” segment); and the development, manufacture, and sale of software and sensors, which includes the sale of devices, wearables, applications, cloud and mobile products, and services (collectively, the “Software and Sensors” segment). In both segments, we report sales of products and services. Service revenue in both segments includes sales related to Axon Evidence. In the Software and Sensors segment, service revenue also includes other recurring cloud-hosted software revenue and related professional services. Collectively, this revenue is sometimes referred to as "Axon Cloud revenue." Reportable segments are determined based on discrete financial information reviewed by our Chief Executive Officer who is our chief operating decision maker ("CODM"). We organize and review operations based on products and services, and currently there are no operating segments that are aggregated. We perform an analysis of our reportable segments at least annually. Additional information related to our business segments is summarized in Note 13. |
Geographic Information and Major Customers / Suppliers | Geographic Information and Major Customers / Suppliers For the three months ended March 31, 2021, no individual country outside the U.S. represented more than 10% of total net sales. Individual sales transactions in the international market are generally larger and occur more intermittently than in the domestic market due to the profile of our customers. For the three months ended March 31, 2021, no customer represented more than 10% of total net sales. At March 31, 2021 and December 31, 2020, no customer represented more than 10% of the aggregate balance of accounts and notes receivable and contract assets. We currently purchase both off the shelf and custom components, including, but not limited to, finished circuit boards, injection-molded plastic components, small machined parts, custom cartridge components, electronic components, and off the shelf sub-assemblies from suppliers located in the U.S., Canada, China, Israel, Republic of Korea, Mexico, Sri Lanka, and Taiwan. Although we currently obtain many of these components from single source suppliers, we own the injection molded component tooling, most of the designs, and the test fixtures used in their production for all custom components. As a result, we believe we could obtain alternative suppliers in most cases without incurring significant production delays. We also strategically hold safety stock levels on custom components to further reduce this risk. For off the shelf components, we believe that in most cases there are readily available alternative suppliers who can consistently meet our needs for these components. We acquire most of our components on a purchase order basis and do not have any significant long-term contracts with component suppliers. |
Income per Common Share | Income per Common Share Basic income per common share is computed by dividing net income by the weighted average number of common shares outstanding during the periods presented. Diluted income per share reflects the potential dilution from outstanding stock options and unvested restricted stock units. The calculation of the weighted average number of shares outstanding and earnings per share are as follows (in thousands except per share data): Three Months Ended March 31, 2021 2020 Numerator for basic and diluted earnings per share: Net income (loss) $ (47,917) $ 4,074 Denominator: Weighted average shares outstanding 64,036 59,609 Dilutive effect of stock-based awards — 785 Diluted weighted average shares outstanding 64,036 60,394 Anti-dilutive stock-based awards excluded 12,234 12,161 Net income (loss) per common share: Basic $ (0.75) $ 0.07 Diluted $ (0.75) $ 0.07 |
Standard Warranties | Standard Warranties We warranty our CEDs, Axon cameras and certain related accessories from manufacturing defects on a limited basis for a period of one year after purchase and, thereafter, will repair or replace any defective unit for a fee. Estimated costs for the standard warranty are charged to cost of products sold when revenue is recorded for the related product. Future warranty costs are estimated based on historical data related to warranty claims and this rate is applied to current product sales. Historically, reserve amounts have been increased if management becomes aware of a component failure or other issue that could result in larger than anticipated warranty claims from customers. The warranty reserve is reviewed quarterly to verify that it sufficiently reflects the remaining warranty obligations based on the anticipated expenditures over the balance of the warranty obligation period, and adjustments are made when actual warranty claim experience differs from estimates. The warranty reserve is included in accrued liabilities on the accompanying condensed consolidated balance sheets. Changes in our estimated product warranty liabilities were as follows (in thousands): Three Months Ended March 31, 2021 2020 Balance, beginning of period $ 769 $ 1,476 Utilization of reserve (231) (171) Warranty expense (benefit) 406 (85) Balance, end of period $ 944 $ 1,220 |
Fair Value Measurements and Financial Instruments | Fair Value Measurements and Financial Instruments We use the fair value framework that prioritizes the inputs to valuation techniques for measuring financial assets and liabilities measured on a recurring basis and for non-financial assets and liabilities when these items are re-measured. Fair value is considered to be the exchange price in an orderly transaction between market participants, to sell an asset or transfer a liability at the measurement date. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. We categorize each of our fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: ● Level 1 – Valuation techniques in which all significant inputs are unadjusted quoted prices from active markets for assets or liabilities that are identical to the assets or liabilities being measured. ● Level 2 – Valuation techniques in which significant inputs include quoted prices from active markets for assets or liabilities that are similar to the assets or liabilities being measured and/or quoted prices for assets or liabilities that are identical or similar to the assets or liabilities being measured from markets that are not active. Also, model-derived valuations in which all significant inputs and significant value drivers are observable in active markets are Level 2 valuation techniques. ● Level 3 – Valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Unobservable inputs are valuation technique inputs that reflect our own assumptions about inputs that market participants would use in pricing an asset or liability. We have cash equivalents and investments, which at March 31, 2021 and December 31, 2020 were comprised of money market funds, certificates of deposit, commercial paper, corporate bonds, municipal bonds, U.S. Government agency bonds, U.S. Treasury bills, and U.S. Treasury inflation-protected securities. Also included in cash equivalents and investments at December 31, 2020 were U.S. Treasury repurchase agreements. See additional disclosure regarding the fair value of our cash equivalents and investments in Note 3. Included in the balance of other assets as of March 31, 2021 and December 31, 2020 was $4.8 million and $4.7 million, respectively, related to corporate-owned life insurance policies which are used to fund our deferred compensation plan. We determine the fair value of insurance contracts by obtaining the cash surrender value of the contracts from the issuer, a Level 2 valuation technique. We have strategic investments in three unconsolidated affiliates, which are included within other assets. The estimated fair value of the investments was determined based on Level 3 inputs. As of March 31, 2021, management estimated that the fair value of the investments equaled the carrying value. Our financial instruments also include accounts and notes receivable, accounts payable and accrued liabilities. Due to the short-term nature of these instruments, their fair values approximate their carrying values on the balance sheet. |
Restricted cash | Restricted Cash Restricted cash balances as of March 31, 2021 and December 31, 2020 included $0.1 million primarily related to funds held in an international bank account for a country in which we are required to maintain a minimum balance to operate. Approximately half of the balance was included in prepaid expenses and other current assets on our condensed consolidated balance sheets, with the remainder included in other assets. |
Valuation of Goodwill, Intangibles and Long-lived Assets | Valuation of Goodwill, Intangibles and Long-lived Assets We evaluate whether events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets, excluding goodwill and intangible assets with indefinite useful lives, may warrant revision or that the remaining balance of these assets may not be recoverable. Such circumstances could include, but are not limited to, a change in the product mix, a change in the way products are created, produced or delivered, or a significant change in the way products are branded and marketed. In performing the review for recoverability, we estimate the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. The amount of the impairment loss, if impairment exists, is calculated based on the excess of the carrying amounts of the assets over their estimated fair value computed using discounted cash flows. We do not amortize goodwill and intangible assets with indefinite useful lives; rather such assets are required to be tested for impairment at least annually or sooner whenever events or changes in circumstances indicate that the assets may be impaired. We perform our annual goodwill and intangible asset impairment tests in the fourth quarter of each year. |
Recently Issued Accounting Guidance | Recently Issued Accounting Guidance Recently Adopted Accounting Pronouncements In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12, Simplifying the Accounting for Income Taxes. Adoption of this ASU on January 1, 2021 did not have a material impact on our consolidated financial statements. In January 2020, the FASB issued ASU No. 2020-01, Investments – Equity Securities (Topic 321), Investments – Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) – Clarifying the Interactions Between Topic 321, Topic 323, and Topic 815 (a Consensus of the Emerging Issues Task Force). The guidance clarifies the interaction between ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities and the ASU on equity method investments. ASU 2016-01 provides companies with an alternative to measure certain equity securities without a readily determinable fair value at cost, minus impairment, if any, unless an observable transaction for an identical or similar security occurs. ASU 2020-01 clarifies that for purposes of applying the Topic 321 measurement alternative, an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting under Topic 323, immediately before applying or upon discontinuing the equity method. In addition, the new ASU provides direction that a company should not consider whether the underlying securities would be accounted for under the equity method or the fair value option when it is determining the accounting for certain forward contracts and purchased options, upon either settlement or exercise. Adoption of this ASU on January 1, 2021 did not have a material impact on our consolidated financial statements. |
Reclassification of Prior Year Presentation | Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications are not material and had no effect on the reported results of operations. |
Organization and Summary of S_3
Organization and Summary of Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Weighted Average Number of Shares Outstanding and Income Per Share | Three Months Ended March 31, 2021 2020 Numerator for basic and diluted earnings per share: Net income (loss) $ (47,917) $ 4,074 Denominator: Weighted average shares outstanding 64,036 59,609 Dilutive effect of stock-based awards — 785 Diluted weighted average shares outstanding 64,036 60,394 Anti-dilutive stock-based awards excluded 12,234 12,161 Net income (loss) per common share: Basic $ (0.75) $ 0.07 Diluted $ (0.75) $ 0.07 |
Summary of Changes in Estimated Product Warranty Liabilities | Changes in our estimated product warranty liabilities were as follows (in thousands): Three Months Ended March 31, 2021 2020 Balance, beginning of period $ 769 $ 1,476 Utilization of reserve (231) (171) Warranty expense (benefit) 406 (85) Balance, end of period $ 944 $ 1,220 |
Revenues (Tables)
Revenues (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Revenue from Contract with Customer [Abstract] | |
Summary of Revenue by Product and Service Offering and Geography | The following tables present our revenues by primary product and service offering (in thousands): Three Months Ended March 31, 2021 Three Months Ended March 31, 2020 Software and Software and TASER Sensors Total TASER Sensors Total TASER 7 $ 33,991 $ — $ 33,991 $ 15,326 $ — $ 15,326 TASER X26P 9,963 — 9,963 11,061 — 11,061 TASER X2 12,778 — 12,778 14,075 — 14,075 TASER Pulse 2,205 — 2,205 1,200 — 1,200 Cartridges 30,418 — 30,418 26,625 — 26,625 Axon Body — 19,756 19,756 — 12,823 12,823 Axon Flex — 905 905 — 1,183 1,183 Axon Fleet — 3,763 3,763 — 4,775 4,775 Axon Dock — 6,920 6,920 — 4,951 4,951 Axon Evidence and cloud services 1,396 52,294 53,690 498 39,154 39,652 Extended warranties 5,646 7,500 13,146 4,977 5,458 10,435 Other 2,602 4,882 7,484 2,133 2,923 5,056 Total $ 98,999 $ 96,020 $ 195,019 $ 75,895 $ 71,267 $ 147,162 The following table presents our revenues disaggregated by geography (in thousands): Three Months Ended March 31, 2021 2020 United States $ 160,386 82 % $ 117,463 80 % Other countries 34,633 18 29,699 20 Total $ 195,019 100 % $ 147,162 100 % |
Contract with Customer, Assets and Liabilities | The following table presents our contract assets, contract liabilities and certain information related to these balances as of and for the three months ended March 31, 2021 (in thousands): March 31, 2021 Contract assets, net $ 98,813 Contract liabilities (deferred revenue) 281,193 Revenue recognized in the period from: Amounts included in contract liabilities at the beginning of the period 63,871 Contract liabilities (deferred revenue) consisted of the following (in thousands): March 31, 2021 December 31, 2020 Current Long-Term Total Current Long-Term Total Warranty: TASER $ 10,501 $ 16,486 $ 26,987 $ 11,635 $ 16,953 $ 28,588 Software and Sensors 14,432 5,322 19,754 13,926 5,025 18,951 24,933 21,808 46,741 25,561 21,978 47,539 Hardware: TASER 16,040 15,024 31,064 16,314 14,304 30,618 Software and Sensors 23,723 51,265 74,988 25,181 50,981 76,162 39,763 66,289 106,052 41,495 65,285 106,780 Services: TASER 969 1,997 2,966 996 1,554 2,550 Software and Sensors 99,421 26,013 125,434 95,907 22,405 118,312 100,390 28,010 128,400 96,903 23,959 120,862 Total $ 165,086 $ 116,107 $ 281,193 $ 163,959 $ 111,222 $ 275,181 March 31, 2021 December 31, 2020 Current Long-Term Total Current Long-Term Total TASER $ 27,510 $ 33,507 $ 61,017 $ 28,945 $ 32,811 $ 61,756 Software and Sensors 137,576 82,600 220,176 135,014 78,411 213,425 Total $ 165,086 $ 116,107 $ 281,193 $ 163,959 $ 111,222 $ 275,181 |
Cash, Cash Equivalents and In_2
Cash, Cash Equivalents and Investments (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Cash and Cash Equivalents [Abstract] | |
Summary of Cash, Cash Equivalents and Held-to-Maturity Investments by Type | The following tables summarize our cash, cash equivalents, and held-to-maturity investments at March 31, 2021 and December 31, 2020 (in thousands): As of March 31, 2021 Gross Gross Cash and Amortized Unrealized Unrealized Cash Short-Term Long-Term Cost Gains Losses Fair Value Equivalents Investments Investments Cash $ 137,003 $ — $ — $ 137,003 $ 137,003 $ — $ — Level 1: Money market funds 16,819 — — 16,819 16,819 — — Agency bonds 73,996 94 — 74,090 — 45,995 28,001 Treasury bills 104,184 13 — 104,197 — 104,184 — Subtotal 194,999 107 — 195,106 16,819 150,179 28,001 Level 2: State and municipal obligations 83,086 12 (30) 83,068 — 74,295 8,791 Certificates of deposit 500 — — 500 — 500 — Corporate bonds 186,406 140 (81) 186,465 1,002 143,712 41,692 Treasury inflation-protected securities 3,310 7 — 3,317 — 3,310 — Commercial paper 68,961 — — 68,961 — 68,961 — Subtotal 342,263 159 (111) 342,311 1,002 290,778 50,483 Total $ 674,265 $ 266 $ (111) $ 674,420 $ 154,824 $ 440,957 $ 78,484 As of December 31, 2020 Gross Gross Cash and Amortized Unrealized Unrealized Cash Short-Term Long-Term Cost Gains Losses Fair Value Equivalents Investments Investments Cash $ 116,107 $ — $ — $ 116,107 $ 116,107 $ — $ — Level 1: Money market funds 23,611 — — 23,611 23,611 — — Agency bonds 63,794 122 — 63,916 — 23,794 40,000 Treasury Bills 96,384 6 — 96,390 96,384 Subtotal 183,789 128 — 183,917 23,611 120,178 40,000 Level 2: State and municipal obligations 77,130 25 (28) 77,127 — 66,519 10,611 Certificates of deposit 500 — — 500 — 500 — Corporate bonds 212,825 232 (100) 212,957 2,525 170,205 40,095 U.S. Treasury repurchase agreements 13,200 — — 13,200 13,200 — — Treasury inflation-protected securities 3,291 16 — 3,307 — 3,291 Commercial paper 45,974 — — 45,974 45,974 — Subtotal 352,920 273 (128) 353,065 15,725 286,489 50,706 Total $ 652,816 $ 401 $ (128) $ 653,089 $ 155,443 $ 406,667 $ 90,706 |
Expected Credit Losses (Tables)
Expected Credit Losses (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Expected Credit Losses | |
Schedule of roll-forward of allowance for credit losses | The following table provides a roll-forward of the allowance for expected credit losses that is deducted from the amortized cost basis of accounts receivable, notes receivable, and contract assets to present the net amount expected to be collected (in thousands): Three Months Ended March 31, 2021 United States Other countries Total Balance, beginning of period $ 2,902 $ 474 $ 3,376 Provision for expected credit losses (99) (205) (304) Amounts written off charged against the allowance (39) - (39) Other, including foreign currency translation 134 1 135 Balance, end of period $ 2,898 $ 270 $ 3,168 |
Schedule of allowance for expected credit losses for each type of customer receivable | March 31, December 31, 2021 2020 Accounts receivable and notes receivable, current $ 1,796 $ 2,105 Contract assets, net 991 794 Long-term notes receivable, net of current portion 381 477 Total allowance for expected credit losses on customer receivables $ 3,168 $ 3,376 |
Inventory (Tables)
Inventory (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Inventory Disclosure [Abstract] | |
Inventory | March 31, 2021 December 31, 2020 Raw materials $ 33,918 $ 39,194 Finished goods 55,739 50,764 Total inventory $ 89,657 $ 89,958 |
Other Long-Term Assets (Tables)
Other Long-Term Assets (Tables) | 1 Months Ended |
Mar. 31, 2021 | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |
Schedule of Other Long-Term Assets | Other long-term assets consisted of the following at March 31, 2021 and December 31, 2020 (in thousands): March 31, 2021 December 31, 2020 Cash surrender value of corporate-owned life insurance policies $ 4,806 $ 4,654 Deferred commissions (1) 32,337 32,455 Restricted cash 59 62 Operating lease assets 23,168 22,308 Strategic investments (2) 29,500 9,500 Warrants for strategic investment (3) 2,211 2,211 Prepaid expenses, deposits and other 10,839 8,727 Total other long-term assets $ 102,920 $ 79,917 (1) Represents the incremental costs of obtaining contracts with customers, which consist primarily of sales commissions. These costs are ascribed to or allocated to the underlying performance obligations in the contracts and amortized consistent with the recognition timing of the revenue for the underlying performance obligations. (2) Strategic investments include investments in non-public technology-driven companies. We account for strategic investments under the ASC 321 measurement alternative for equity securities without readily determinable fair values, as there are no quoted market prices for the investment. The investments are measured at cost less impairment, adjusted for observable price changes and is assessed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. As of March 31, 2021, no impairment was recorded for the investments. We did not recognize any adjustments to the recorded cost bases during the three months ended March 31, 2021. We have recognized an increase of $2.4 million in the cost bases since our initial investment. During the three months ended March 31, 2021, we made a $20.0 million minority investment in RapidSOS, Inc. (3) In conjunction with our strategic investment in and commercial partnership with Flock Group Inc., we have the ability to commit additional capital over time through warrants where the exercisability and exercise prices are conditional on the achievement of certain partnership performance metrics. The amount reflected in other assets represents the fair value of the preferred stock warrants, as adjusted for observable price changes of $0.4 million during the quarter ended December 31, 2020. |
Accrued Liabilities (Tables)
Accrued Liabilities (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Payables and Accruals [Abstract] | |
Schedule of Accrued liabilities | Accrued liabilities consisted of the following at March 31, 2021 and December 31, 2020 (in thousands): March 31, 2021 December 31, 2020 Accrued salaries, benefits and bonus $ 21,880 $ 36,892 Accrued professional, consulting and lobbying fees 1,318 3,055 Accrued warranty expense 944 769 Accrued income and other taxes 2,482 3,848 Accrued inventory in transit 4,696 4,597 Other accrued expenses 9,777 10,682 Accrued liabilities $ 41,097 $ 59,843 |
Stockholders' Equity (Tables)
Stockholders' Equity (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Equity [Abstract] | |
Equity Compensation Goals | Eight Separate Adjusted EBITDA (CEO Eight Separate Revenue Goals (1) Performance Award) Goals (in thousands) (in thousands) Goal #1, $710,058 Goal #9, $125,000 Goal #2, $860,058 Goal #10, $155,000 Goal #3, $1,010,058 Goal #11, $175,000 Goal #4, $1,210,058 Goal #12, $190,000 Goal #5, $1,410,058 Goal #13, $200,000 Goal #6, $1,610,058 Goal #14, $210,000 Goal #7, $1,810,058 Goal #15, $220,000 Goal #8, $2,010,058 Goal #16, $230,000 (1) In connection with the business acquisition that was completed during the three months ended June 30, 2018, the revenue goals were adjusted for the acquiree’s Target Revenue, as defined in the CEO Performance Award agreement. |
Summary of Restricted Stock Unit Activity | The following table summarizes RSU activity for the three months ended March 31, 2021 (number of units and aggregate intrinsic value in thousands): Number of Weighted Average Aggregate Units Grant-Date Fair Value Intrinsic Value Units outstanding, beginning of year 1,107 $ 76.10 Granted 57 152.58 Released (184) 47.57 Forfeited (25) 91.87 Units outstanding, end of period 955 85.76 $ 136,019 |
Summary of Performance Stock Unit Activity | The following table summarizes PSU activity, inclusive of XSUs, for the three months ended March 31, 2021 (number of units and aggregate intrinsic value in thousands): Number of Weighted Average Aggregate Units Grant-Date Fair Value Intrinsic Value Units outstanding, beginning of year 5,618 $ 35.71 Granted 190 43.83 Released (765) 37.61 Forfeited (41) 34.70 Units outstanding, end of period 5,002 35.74 $ 712,357 |
Summary of the Company's Stock Options Activity | The following table summarizes stock option activity for the three months ended March 31, 2021 (number of units and aggregate intrinsic value in thousands): Weighted Weighted Average Number Average Remaining of Exercise Contractual Aggregate Options Price Life (years) Intrinsic Value Options outstanding, beginning of year 6,366 $ 28.58 Granted — — Exercised — — Expired / terminated — — Options outstanding, end of period 6,366 28.58 6.91 $ 724,689 Options exercisable, end of period 1,591 28.58 6.91 181,172 |
Reported Share-Based Compensation | The following table summarizes the composition of stock-based compensation expense for the three months ended March 31, 2021 and 2020 (in thousands): Three Months Ended March 31, 2021 2020 Cost of products sold and services delivered $ 1,489 $ 590 Sales, general and administrative expenses 71,015 14,970 Research and development expenses 17,106 4,635 Total stock-based compensation expense $ 89,610 $ 20,195 |
Segment Data (Tables)
Segment Data (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Segment Reporting [Abstract] | |
Summary of Operational Information Relative to the Company's Reportable Segments | Information relative to our reportable segments was as follows (in thousands): Three Months Ended March 31, 2021 Three Months Ended March 31, 2020 Software and Software and TASER Sensors Total TASER Sensors Total Net sales from products $ 97,302 $ 43,584 $ 140,886 $ 75,175 $ 32,113 $ 107,288 Net sales from services 1,697 52,436 54,133 720 39,154 39,874 Net sales 98,999 96,020 195,019 75,895 71,267 147,162 Cost of product sales 32,945 25,671 58,616 30,248 18,636 48,884 Cost of service sales — 13,050 13,050 — 9,670 9,670 Cost of sales 32,945 38,721 71,666 30,248 28,306 58,554 Gross margin $ 66,054 $ 57,299 $ 123,353 $ 45,647 $ 42,961 $ 88,608 Research and development $ 9,243 $ 37,775 $ 47,018 $ 3,032 $ 23,349 $ 26,381 |
Organization and Summary of S_4
Organization and Summary of Significant Accounting Policies - Narrative (Details) $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2021USD ($)countrycustomersegment | Dec. 31, 2020USD ($)customer | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Number of reportable segments | segment | 2 | |
Warranty period | 1 year | |
Cash surrender value of corporate-owned life insurance policies | $ 4,806 | $ 4,654 |
Restricted cash balance | 59 | 62 |
Prepaid Expenses and Other Current Assets | ||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Restricted cash balance | $ 100 | $ 100 |
Net Sales | Geographic Concentration Risk | ||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Number of countries outside the U.S. representing more than 10% of total net sales | country | 0 | |
Net Sales | Customer Concentration Risk | ||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Number of major customers | customer | 0 | |
Accounts and notes receivable and contract assets | Customer Concentration Risk | ||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Number of major customers | customer | 0 | 0 |
Organization and Summary of S_5
Organization and Summary of Significant Accounting Policies - Weighted Average Number of Shares Outstanding and Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Numerator for basic and diluted earnings per share: | ||
Net income (loss) | $ (47,917) | $ 4,074 |
Denominator: | ||
Weighted average shares outstanding basic (in shares) | 64,036 | 59,609 |
Dilutive effect of stock-based awards (in shares) | 785 | |
Diluted weighted average shares outstanding (in shares) | 64,036 | 60,394 |
Anti-dilutive stock-based awards excluded (in shares) | 12,234 | 12,161 |
Net income (loss) per share: | ||
Basic (in dollars per share) | $ (0.75) | $ 0.07 |
Diluted (in dollars per share) | $ (0.75) | $ 0.07 |
Organization and Summary of S_6
Organization and Summary of Significant Accounting Policies - Summary of Changes in Estimated Product Warranty Liabilities (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Movement in Standard and Extended Product Warranty | ||
Balance, beginning of period | $ 769 | $ 1,476 |
Utilization of reserve | (231) | (171) |
Warranty expense (benefit) | 406 | (85) |
Balance, end of period | $ 944 | $ 1,220 |
Revenues - Revenues By Products
Revenues - Revenues By Products And Service Offerings (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | $ 195,019 | $ 147,162 |
TASER 7 | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 33,991 | 15,326 |
TASER X26P | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 9,963 | 11,061 |
TASER X2 | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 12,778 | 14,075 |
TASER Pulse | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 2,205 | 1,200 |
Cartridges | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 30,418 | 26,625 |
Axon Body | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 19,756 | 12,823 |
Axon Flex | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 905 | 1,183 |
Axon Fleet | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 3,763 | 4,775 |
Axon Dock | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 6,920 | 4,951 |
Axon Evidence and cloud services | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 53,690 | 39,652 |
Extended warranties | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 13,146 | 10,435 |
Other | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 7,484 | 5,056 |
TASER | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 98,999 | 75,895 |
TASER | TASER 7 | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 33,991 | 15,326 |
TASER | TASER X26P | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 9,963 | 11,061 |
TASER | TASER X2 | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 12,778 | 14,075 |
TASER | TASER Pulse | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 2,205 | 1,200 |
TASER | Cartridges | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 30,418 | 26,625 |
TASER | Axon Body | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 0 | |
TASER | Axon Flex | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 0 | |
TASER | Axon Fleet | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 0 | |
TASER | Axon Dock | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 0 | |
TASER | Axon Evidence and cloud services | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 1,396 | 498 |
TASER | Extended warranties | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 5,646 | 4,977 |
TASER | Other | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 2,602 | 2,133 |
Software and Sensors | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 96,020 | 71,267 |
Software and Sensors | TASER 7 | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 0 | |
Software and Sensors | TASER X26P | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 0 | |
Software and Sensors | TASER X2 | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 0 | |
Software and Sensors | TASER Pulse | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 0 | |
Software and Sensors | Cartridges | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 0 | |
Software and Sensors | Axon Body | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 19,756 | 12,823 |
Software and Sensors | Axon Flex | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 905 | 1,183 |
Software and Sensors | Axon Fleet | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 3,763 | 4,775 |
Software and Sensors | Axon Dock | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 6,920 | 4,951 |
Software and Sensors | Axon Evidence and cloud services | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 52,294 | 39,154 |
Software and Sensors | Extended warranties | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | 7,500 | 5,458 |
Software and Sensors | Other | ||
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | ||
Revenue from contract with customers | $ 4,882 | $ 2,923 |
Revenues - Revenues By Geograph
Revenues - Revenues By Geographic Area (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Disaggregation of Revenue [Line Items] | ||
Revenue from contract with customers | $ 195,019 | $ 147,162 |
United States | ||
Disaggregation of Revenue [Line Items] | ||
Revenue from contract with customers | 160,386 | 117,463 |
Other countries | ||
Disaggregation of Revenue [Line Items] | ||
Revenue from contract with customers | $ 34,633 | $ 29,699 |
Revenue from Contract with Customer | Geographic Concentration Risk | ||
Disaggregation of Revenue [Line Items] | ||
Concentration risk (as a percentage) | 100.00% | 100.00% |
Revenue from Contract with Customer | Geographic Concentration Risk | United States | ||
Disaggregation of Revenue [Line Items] | ||
Concentration risk (as a percentage) | 82.00% | 80.00% |
Revenue from Contract with Customer | Geographic Concentration Risk | Other countries | ||
Disaggregation of Revenue [Line Items] | ||
Concentration risk (as a percentage) | 18.00% | 20.00% |
Revenues - Contract Assets, Con
Revenues - Contract Assets, Contract Liabilities (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Dec. 31, 2020 | |
Revenue from Contract with Customer [Abstract] | ||
Contract assets, net | $ 98,813 | |
Contract liabilities (deferred revenue) | 281,193 | $ 275,181 |
Revenue recognized in the period from: | ||
Amounts included in contract liabilities at the beginning of the period | $ 63,871 |
Revenues - Schedule Of Contract
Revenues - Schedule Of Contract Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Disaggregation of Revenue [Line Items] | ||
Current | $ 165,086 | $ 163,959 |
Long-Term | 116,107 | 111,222 |
Total | 281,193 | 275,181 |
TASER | ||
Disaggregation of Revenue [Line Items] | ||
Current | 27,510 | 28,945 |
Long-Term | 33,507 | 32,811 |
Total | 61,017 | 61,756 |
Software and Sensors | ||
Disaggregation of Revenue [Line Items] | ||
Current | 137,576 | 135,014 |
Long-Term | 82,600 | 78,411 |
Total | 220,176 | 213,425 |
Warranty | ||
Disaggregation of Revenue [Line Items] | ||
Current | 24,933 | 25,561 |
Long-Term | 21,808 | 21,978 |
Total | 46,741 | 47,539 |
Warranty | TASER | ||
Disaggregation of Revenue [Line Items] | ||
Current | 10,501 | 11,635 |
Long-Term | 16,486 | 16,953 |
Total | 26,987 | 28,588 |
Warranty | Software and Sensors | ||
Disaggregation of Revenue [Line Items] | ||
Current | 14,432 | 13,926 |
Long-Term | 5,322 | 5,025 |
Total | 19,754 | 18,951 |
Hardware | ||
Disaggregation of Revenue [Line Items] | ||
Current | 39,763 | 41,495 |
Long-Term | 66,289 | 65,285 |
Total | 106,052 | 106,780 |
Hardware | TASER | ||
Disaggregation of Revenue [Line Items] | ||
Current | 16,040 | 16,314 |
Long-Term | 15,024 | 14,304 |
Total | 31,064 | 30,618 |
Hardware | Software and Sensors | ||
Disaggregation of Revenue [Line Items] | ||
Current | 23,723 | 25,181 |
Long-Term | 51,265 | 50,981 |
Total | 74,988 | 76,162 |
Software and Sensors | ||
Disaggregation of Revenue [Line Items] | ||
Current | 100,390 | 96,903 |
Long-Term | 28,010 | 23,959 |
Total | 128,400 | 120,862 |
Software and Sensors | TASER | ||
Disaggregation of Revenue [Line Items] | ||
Current | 969 | 996 |
Long-Term | 1,997 | 1,554 |
Total | 2,966 | 2,550 |
Software and Sensors | Software and Sensors | ||
Disaggregation of Revenue [Line Items] | ||
Current | 99,421 | 95,907 |
Long-Term | 26,013 | 22,405 |
Total | $ 125,434 | $ 118,312 |
Revenues - Revenue Performance
Revenues - Revenue Performance Obligations (Details) $ in Millions | Mar. 31, 2021USD ($) |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue, remaining performance obligation | $ 1,790 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-04-01 | Minimum | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue, remaining performance obligation to be recognized in the next twelve months (as a percentage) | 20.00% |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 5 years |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-04-01 | Maximum | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue, remaining performance obligation to be recognized in the next twelve months (as a percentage) | 25.00% |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 12 months |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2028-04-01 | Maximum | |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] | |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 7 years |
Cash, Cash Equivalents, and Inv
Cash, Cash Equivalents, and Investments (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Restricted Cash and Cash Equivalents Items [Line Items] | ||
Amortized Cost | $ 674,265 | $ 652,816 |
Gross Unrealized Gains | 266 | 401 |
Gross Unrealized Losses | (111) | (128) |
Fair Value | 674,420 | 653,089 |
Cash and Cash Equivalents | 154,824 | 155,443 |
Short-Term Investments | 440,957 | 406,667 |
Long-Term Investments | 78,484 | 90,706 |
Credit loss reserve for held-to-maturity investments | 100 | 100 |
Fair Value, Inputs, Level 1 | ||
Restricted Cash and Cash Equivalents Items [Line Items] | ||
Amortized Cost | 194,999 | 183,789 |
Gross Unrealized Gains | 107 | 128 |
Gross Unrealized Losses | 0 | |
Fair Value | 195,106 | 183,917 |
Cash and Cash Equivalents | 16,819 | 23,611 |
Short-Term Investments | 150,179 | 120,178 |
Long-Term Investments | 28,001 | 40,000 |
Fair Value, Inputs, Level 2 | ||
Restricted Cash and Cash Equivalents Items [Line Items] | ||
Amortized Cost | 342,263 | 352,920 |
Gross Unrealized Gains | 159 | 273 |
Gross Unrealized Losses | (111) | (128) |
Fair Value | 342,311 | 353,065 |
Cash and Cash Equivalents | 1,002 | 15,725 |
Short-Term Investments | 290,778 | 286,489 |
Long-Term Investments | 50,483 | 50,706 |
Cash | ||
Restricted Cash and Cash Equivalents Items [Line Items] | ||
Amortized Cost | 137,003 | 116,107 |
Gross Unrealized Losses | 0 | |
Fair Value | 137,003 | 116,107 |
Cash and Cash Equivalents | 137,003 | 116,107 |
Short-Term Investments | 0 | |
Money market funds | Fair Value, Inputs, Level 1 | ||
Restricted Cash and Cash Equivalents Items [Line Items] | ||
Amortized Cost | 16,819 | 23,611 |
Gross Unrealized Losses | 0 | |
Fair Value | 16,819 | 23,611 |
Cash and Cash Equivalents | 16,819 | 23,611 |
Short-Term Investments | 0 | |
Agency bonds | Fair Value, Inputs, Level 1 | ||
Restricted Cash and Cash Equivalents Items [Line Items] | ||
Amortized Cost | 73,996 | 63,794 |
Gross Unrealized Gains | 94 | 122 |
Gross Unrealized Losses | 0 | |
Fair Value | 74,090 | 63,916 |
Cash and Cash Equivalents | 0 | |
Short-Term Investments | 45,995 | 23,794 |
Long-Term Investments | 28,001 | 40,000 |
Treasury bills | Fair Value, Inputs, Level 1 | ||
Restricted Cash and Cash Equivalents Items [Line Items] | ||
Amortized Cost | 104,184 | 96,384 |
Gross Unrealized Gains | 13 | 6 |
Gross Unrealized Losses | 0 | |
Fair Value | 104,197 | 96,390 |
Short-Term Investments | 104,184 | 96,384 |
State and municipal obligations | Fair Value, Inputs, Level 2 | ||
Restricted Cash and Cash Equivalents Items [Line Items] | ||
Amortized Cost | 83,086 | 77,130 |
Gross Unrealized Gains | 12 | 25 |
Gross Unrealized Losses | (30) | (28) |
Fair Value | 83,068 | 77,127 |
Cash and Cash Equivalents | 0 | |
Short-Term Investments | 74,295 | 66,519 |
Long-Term Investments | 8,791 | 10,611 |
Certificates of deposit | Fair Value, Inputs, Level 2 | ||
Restricted Cash and Cash Equivalents Items [Line Items] | ||
Amortized Cost | 500 | 500 |
Gross Unrealized Losses | 0 | |
Fair Value | 500 | 500 |
Cash and Cash Equivalents | 0 | |
Short-Term Investments | 500 | 500 |
Corporate bonds | Fair Value, Inputs, Level 2 | ||
Restricted Cash and Cash Equivalents Items [Line Items] | ||
Amortized Cost | 186,406 | 212,825 |
Gross Unrealized Gains | 140 | 232 |
Gross Unrealized Losses | (81) | (100) |
Fair Value | 186,465 | 212,957 |
Cash and Cash Equivalents | 1,002 | 2,525 |
Short-Term Investments | 143,712 | 170,205 |
Long-Term Investments | 41,692 | 40,095 |
U.S. Treasury repurchase agreements | Fair Value, Inputs, Level 2 | ||
Restricted Cash and Cash Equivalents Items [Line Items] | ||
Amortized Cost | 13,200 | |
Gross Unrealized Losses | 0 | |
Fair Value | 13,200 | |
Cash and Cash Equivalents | 13,200 | |
Short-Term Investments | 0 | |
Treasury inflation - protected securities | Fair Value, Inputs, Level 2 | ||
Restricted Cash and Cash Equivalents Items [Line Items] | ||
Amortized Cost | 3,310 | 3,291 |
Gross Unrealized Gains | 7 | 16 |
Gross Unrealized Losses | 0 | |
Fair Value | 3,317 | 3,307 |
Cash and Cash Equivalents | 0 | |
Short-Term Investments | 3,310 | 3,291 |
Commercial paper | Fair Value, Inputs, Level 2 | ||
Restricted Cash and Cash Equivalents Items [Line Items] | ||
Amortized Cost | 68,961 | 45,974 |
Gross Unrealized Losses | 0 | |
Fair Value | 68,961 | 45,974 |
Short-Term Investments | $ 68,961 | $ 45,974 |
Expected Credit Losses (Details
Expected Credit Losses (Details) $ in Thousands | 3 Months Ended |
Mar. 31, 2021USD ($) | |
Accounts Receivable, Allowance for Credit Loss [Roll Forward] | |
Balance, beginning of period | $ 3,376 |
Provision for expected credit losses | (304) |
Amounts written off charged against the allowance | (39) |
Other, including foreign currency translation | 135 |
Balance, end of period | 3,168 |
United States | |
Accounts Receivable, Allowance for Credit Loss [Roll Forward] | |
Balance, beginning of period | 2,902 |
Provision for expected credit losses | (99) |
Amounts written off charged against the allowance | (39) |
Other, including foreign currency translation | 134 |
Balance, end of period | 2,898 |
Other countries | |
Accounts Receivable, Allowance for Credit Loss [Roll Forward] | |
Balance, beginning of period | 474 |
Provision for expected credit losses | (205) |
Other, including foreign currency translation | 1 |
Balance, end of period | 270 |
COVID-19 | |
Accounts Receivable, Allowance for Credit Loss [Roll Forward] | |
Additional reserve for credit loss | $ 800 |
Expected Credit Losses - Type O
Expected Credit Losses - Type Of Customer Receivable (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Expected Credit Losses | ||
Accounts receivable and notes receivable, current | $ 1,796 | $ 2,105 |
Contract assets, net | 991 | 794 |
Long-term notes receivable, net of current portion | 381 | 477 |
Total allowance for expected credit losses on customer receivables | $ 3,168 | $ 3,376 |
Inventory (Details)
Inventory (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 33,918 | $ 39,194 |
Finished goods | 55,739 | 50,764 |
Total inventory | $ 89,657 | $ 89,958 |
Other Long-Term Assets (Details
Other Long-Term Assets (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Dec. 31, 2020 | |
Schedule of Investments [Line Items] | ||
Cash surrender value of corporate-owned life insurance policies | $ 4,806 | $ 4,654 |
Deferred commissions | 32,337 | 32,455 |
Restricted cash | 59 | 62 |
Operating lease assets | 23,168 | 22,308 |
Strategic investments | 29,500 | 9,500 |
Warrants for strategic investment | 2,211 | 2,211 |
Prepaid expenses, deposits and other | 10,839 | 8,727 |
Total other long-term assets | 102,920 | 79,917 |
Investment, impairment recorded | 0 | |
Increase of cost basis recognized | 2,400 | |
Other Assets | ||
Schedule of Investments [Line Items] | ||
Fair value of warrants | $ 400 | |
RapidSos | ||
Schedule of Investments [Line Items] | ||
Strategic investments | $ 20,000 |
Accrued Liabilities (Details)
Accrued Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 | Mar. 31, 2020 | Dec. 31, 2019 |
Payables and Accruals [Abstract] | ||||
Accrued salaries, benefits and bonus | $ 21,880 | $ 36,892 | ||
Accrued professional, consulting and lobbying fees | 1,318 | 3,055 | ||
Accrued warranty expense | 944 | 769 | $ 1,220 | $ 1,476 |
Accrued income and other taxes | 2,482 | 3,848 | ||
Accrued inventory in transit | 4,696 | 4,597 | ||
Other accrued expenses | 9,777 | 10,682 | ||
Accrued liabilities | $ 41,097 | $ 59,843 |
Income Taxes (Details)
Income Taxes (Details) $ in Millions | 3 Months Ended |
Mar. 31, 2021USD ($) | |
Tax Credit Carryforward [Line Items] | |
Deferred tax assets, net | $ 45.7 |
Liability for unrecognized tax benefits | 7.2 |
Research and development tax credit studies | $ 2.7 |
Effective tax rate (as a percentage) | 3.50% |
Effective tax rate, before discrete period adjustment (as a percentage) | (20.50%) |
Restricted Stock Units (RSUs) | |
Tax Credit Carryforward [Line Items] | |
Discrete tax benefit, stock-based compensation | $ 11.7 |
State Tax | |
Tax Credit Carryforward [Line Items] | |
Unrecognized tax benefits recognized during period | $ 7.2 |
Stockholders' Equity - CEO Perf
Stockholders' Equity - CEO Performance Award - Additional Information (Details) $ in Thousands | May 24, 2018USD ($)trancheitemshares | Mar. 31, 2021USD ($)shares |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
First tranche | $ 2,500,000 | |
Market capitalization goal increment | $ 1,000,000 | |
Recorded share-based compensation expense | $ 132,400 | |
Number of options expected to vest | shares | 5,800,000 | |
Revenue goal number 1 | $ 710,058 | |
Adjusted EBITDA goal number 9 | 125,000 | |
Revenue goal number 2 | 860,058 | |
Adjusted EBITDA goal number 10 | 155,000 | |
Revenue goal number 3 | 1,010,058 | |
Adjusted EBITDA goal number 11 | 175,000 | |
Revenue goal number 4 | 1,210,058 | |
Adjusted EBITDA goal number 12 | 190,000 | |
Revenue goal number 5 | 1,410,058 | |
Adjusted EBITDA goal number 13 | 200,000 | |
Revenue goal number 6 | 1,610,058 | |
Adjusted EBITDA goal number 14 | 210,000 | |
Revenue goal number 7 | 1,810,058 | |
Adjusted EBITDA goal number 15 | 220,000 | |
Revenue goal number 8 | 2,010,058 | |
Adjusted EBITDA goal number 16 | 230,000 | |
Performance Shares | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Performance shares authorized (in shares) | shares | 6,365,856 | |
Updated estimates, stock-based compensation expense | $ 51,400 | |
Number of options vested | shares | 500,000 | |
Weighted average period over which costs are recognized | 3 years 2 months 1 day | |
CEO Performance Award | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Unrecognized share-based compensation cost related to unvested stock option awards, probable of achievement | $ 113,600 | |
Chief Executive Officer | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Number of vesting tranches of share-based awards | tranche | 12 | |
Vesting period | 10 years | |
Number of performance goals, revenue | item | 8 | |
Number of performance goals, adjusted EBITDA | item | 8 |
Stockholders' Equity - eXponent
Stockholders' Equity - eXponential Stock Performance Plan (Details) $ in Millions | Feb. 12, 2019USD ($)itemtranche | May 24, 2018USD ($)shares | Mar. 31, 2021USD ($)shares | Mar. 31, 2020shares |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
First tranche | $ 2,500 | |||
Market capitalization goal increment | $ 1,000 | |||
Recorded share-based compensation expense | $ 132.4 | |||
Number of options expected to vest | shares | 5,800,000 | |||
eXponential Stock Units | 2019 eXponential Stock Performance Plan | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Performance shares authorized (in shares) | shares | 10,000 | 43,000 | ||
Expiration period | 9 years | |||
Number of vesting tranches of share-based awards | tranche | 12 | |||
First tranche | $ 2,500 | |||
Number of performance goals, revenue | item | 8 | |||
Number of performance goals, adjusted EBITDA | item | 8 | |||
Market capitalization goal increment | $ 1,000 | |||
Anti-dilution provision, maximum shares growth rate per year | 3.00% | |||
Recorded share-based compensation expense | $ 94.8 | |||
Unrecognized stock-based compensation expense | $ 96.7 | |||
Weighted average period over which costs are recognized | 3 years | |||
eXponential Stock Units | 2019 eXponential Stock Performance Plan | Eleven Operational Goals | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Number of options expected to vest | shares | 4,900,000 | |||
Performance Shares | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Performance shares authorized (in shares) | shares | 6,365,856 | |||
Weighted average period over which costs are recognized | 3 years 2 months 1 day |
Stockholders' Equity - Summary
Stockholders' Equity - Summary of RSU and PSU Activity (Details) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended |
Mar. 31, 2021USD ($)$ / sharesshares | |
Restricted Stock Units (RSUs) | |
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] | |
Number of Units outstanding, beginning of year (in shares) | shares | 1,107 |
Number of Units, Granted (in shares) | shares | 57 |
Number of Units, Released (in shares) | shares | (184) |
Number of Units, Forfeited (in shares) | shares | (25) |
Number of Units outstanding, end of period (in shares) | shares | 955 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] | |
Weighted Average Grant Date Fair Value, Units outstanding, beginning of year (in dollars per share) | $ / shares | $ 76.10 |
Weighted Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares | 152.58 |
Weighted Average Grant Date Fair Value, Released (in dollars per share) | $ / shares | 47.57 |
Weighted Average Grant Date Fair Value, Forfeited (in dollars per share) | $ / shares | 91.87 |
Weighted Average Grant Date Fair Value, Units outstanding, end of period (in dollars per share) | $ / shares | $ 85.76 |
Aggregate intrinsic value at end of period | $ | $ 136,019 |
Performance Stock Units (PSUs) | |
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] | |
Number of Units outstanding, beginning of year (in shares) | shares | 5,618 |
Number of Units, Granted (in shares) | shares | 190 |
Number of Units, Released (in shares) | shares | (765) |
Number of Units, Forfeited (in shares) | shares | (41) |
Number of Units outstanding, end of period (in shares) | shares | 5,002 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] | |
Weighted Average Grant Date Fair Value, Units outstanding, beginning of year (in dollars per share) | $ / shares | $ 35.71 |
Weighted Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares | 43.83 |
Weighted Average Grant Date Fair Value, Released (in dollars per share) | $ / shares | 37.61 |
Weighted Average Grant Date Fair Value, Forfeited (in dollars per share) | $ / shares | 34.70 |
Weighted Average Grant Date Fair Value, Units outstanding, end of period (in dollars per share) | $ / shares | $ 35.74 |
Aggregate intrinsic value at end of period | $ | $ 712,357 |
Stockholders' Equity - RSU and
Stockholders' Equity - RSU and PSU - Additional Information (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | Mar. 08, 2021 | Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Recorded share-based compensation expense | $ 132,400 | |||
Tax payments, for net share settlement of share based award | $ 7,045 | $ 5,190 | ||
Stock Options | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Aggregate intrinsic value price per share (in dollars per share) | $ 142.42 | |||
Restricted Stock Units (RSUs) | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Aggregate intrinsic value price per share (in dollars per share) | $ 142.42 | |||
Unrecognized stock-based compensation expense | $ 64,300 | |||
Weighted average period over which costs are recognized | 2 years 2 months 19 days | |||
Number of shares vested | 184 | |||
Number of units outstanding (in shares) | 955 | 1,107 | ||
Shares withheld, for net share settlement of share based award (in shares) | 100 | |||
Tax payments, for net share settlement of share based award | $ 6,900 | |||
Performance Stock Units (PSUs) | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Aggregate intrinsic value price per share (in dollars per share) | $ 142.42 | |||
Unrecognized stock-based compensation expense | $ 100,700 | |||
Weighted average period over which costs are recognized | 2 years 11 months 23 days | |||
Performance criteria had been met (in shares) | 900 | |||
Number of shares vested | 765 | |||
Number of units outstanding (in shares) | 5,002 | 5,618 | ||
Shares withheld, for net share settlement of share based award (in shares) | 2 | |||
Tax payments, for net share settlement of share based award | $ 100 | |||
eXponential Stock Units | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Percentage of vesting | 4.00% | |||
Modification, number of shares vested | 13 | |||
Modification, stock-based compensation expense | $ 400 |
Stockholders' Equity - Summar_2
Stockholders' Equity - Summary of the Company's Stock Options Activity (Details) - Stock Options $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended |
Mar. 31, 2021USD ($)$ / sharesshares | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] | |
Number of options, Options outstanding, beginning of year (in shares) | 6,366 |
Number of options, Exercised (in shares) | 0 |
Number of options, Options outstanding, end of year (in shares) | 6,366 |
Number of options, Options exercisable, end of period (in shares) | 1,591 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] | |
Weighted average exercise price, Options outstanding, beginning of year (in dollars per share) | $ / shares | $ 28.58 |
Weighted average exercise price, Options outstanding, end of period (in dollars per share) | $ / shares | 28.58 |
Weighted average exercise price, Options exercisable, end of period (in dollars per share) | $ / shares | $ 28.58 |
Weighted average remaining contractual life, Options outstanding, end of period | 6 years 10 months 28 days |
Weighted average remaining contractual life, Options exercisable, end of period | 6 years 10 months 28 days |
Aggregate intrinsic value, Options outstanding, end of period | $ | $ 724,689 |
Aggregate intrinsic value, Options exercisable, end of period | $ | $ 181,172 |
Stockholders' Equity - Stock Op
Stockholders' Equity - Stock Option Activity - Additional Information (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions | 3 Months Ended | ||
Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | |
Stock Options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Aggregate intrinsic value price per share (in dollars per share) | $ 142.42 | ||
Number of options, Exercised (in shares) | 0 | ||
Total intrinsic value of options exercised | $ 0.3 | ||
Number of options outstanding (in shares) | 6,366 | 6,366 | |
Performance Shares | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Number of options outstanding (in shares) | 4,800 |
Stockholders' Equity - Reported
Stockholders' Equity - Reported Share-Based Compensation (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Stock-based compensation expense | $ 89,610 | $ 20,195 |
Cost of products sold and services delivered | ||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Stock-based compensation expense | 1,489 | 590 |
Sales, general and administrative expenses | ||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Stock-based compensation expense | 71,015 | 14,970 |
Research and development expenses | ||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ||
Stock-based compensation expense | $ 17,106 | $ 4,635 |
Stockholders' Equity - Stock Re
Stockholders' Equity - Stock Repurchase Plan - Additional Information (Details) - USD ($) | 3 Months Ended | |||
Mar. 31, 2021 | Mar. 31, 2020 | Feb. 28, 2019 | Feb. 29, 2016 | |
2019 Stock Incentive Plan | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Common stock reserved for issuance (in shares) | 6,000,000 | |||
Shares available for grant under the plan (in shares) | 1,900,000 | |||
2016 Stock Incentive Plan | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Outstanding common stock repurchase program authorized amount (up to) | $ 50,000,000 | |||
Shares repurchased during period (in shares) | 0 | 0 | ||
Remaining authorized repurchase amount | $ 16,300,000 |
Line of Credit (Details)
Line of Credit (Details) | 3 Months Ended | |
Mar. 31, 2021USD ($) | Dec. 31, 2020USD ($) | |
Debt Instrument [Line Items] | ||
Maximum ratio of total liabilities to tangible net worth | 2.50 | |
Line of Credit | ||
Debt Instrument [Line Items] | ||
Accordion feature allowing for increase in borrowing capacity | $ 100,000,000 | |
Letters of credit outstanding amount | 6,100,000 | |
Available borrowing under letter of credit | 43,900,000 | |
Line of credit borrowings | $ 0 | $ 0 |
EBITDA ratio | 0 | |
Line of Credit | Unsecured Revolving Line of Credit | ||
Debt Instrument [Line Items] | ||
Total availability under line of credit agreement | $ 50,000,000 | |
Line of Credit | Letter of Credit | ||
Debt Instrument [Line Items] | ||
Available borrowing under letter of credit | $ 20,000,000 | |
Minimum | Line of Credit | London Interbank Offered Rate (LIBOR) | ||
Debt Instrument [Line Items] | ||
Debt instrument basis spread on variable rate (as a percentage) | 1.00% | |
Maximum | Line of Credit | London Interbank Offered Rate (LIBOR) | ||
Debt Instrument [Line Items] | ||
Debt instrument basis spread on variable rate (as a percentage) | 1.50% |
Commitments and Contingencies (
Commitments and Contingencies (Details) | Apr. 08, 2021USD ($)$ / sharesshares | Mar. 31, 2021USD ($)lawsuit |
Loss Contingencies [Line Items] | ||
Number of lawsuits against Company | lawsuit | 5 | |
Self insurance on product claim | $ 5,000,000 | |
Subsequent Event | Share Purchase Agreement with Cellebrite DI Ltd | ||
Loss Contingencies [Line Items] | ||
Number of shares of common stock expected to be purchased | shares | 9,000,000 | |
Share price | $ / shares | $ 10 | |
Expected investment amount | $ 90,000,000 | |
Pending dismissal | ||
Loss Contingencies [Line Items] | ||
Number of lawsuits against Company | lawsuit | 1 | |
Line of Credit | ||
Loss Contingencies [Line Items] | ||
Letters of credit outstanding amount | $ 6,100,000 | |
Outstanding letters of credit and bank guarantees not drawn against credit facility | 2,000,000 | |
Surety Bond | ||
Loss Contingencies [Line Items] | ||
Bonds outstanding | 21,500,000 | |
Expire in January 2022 and March 2022 | Surety Bond | ||
Loss Contingencies [Line Items] | ||
Letters of credit outstanding amount | 6,100,000 | |
Expiring in 2021 | Surety Bond | ||
Loss Contingencies [Line Items] | ||
Bonds outstanding | 400,000 | |
Expiring in 2022 | Surety Bond | ||
Loss Contingencies [Line Items] | ||
Bonds outstanding | 3,100,000 | |
Expiring in 2023 | Surety Bond | ||
Loss Contingencies [Line Items] | ||
Bonds outstanding | 7,500,000 | |
Expiring in 2024 | Surety Bond | ||
Loss Contingencies [Line Items] | ||
Bonds outstanding | $ 10,500,000 |
Employee Benefit Plans (Details
Employee Benefit Plans (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Defined Benefit Plan Disclosure [Line Items] | ||
Employee deferrals deemed vested upon contribution (as a percentage) | 100.00% | |
Defined contribution plan, cost | $ 2.1 | $ 1.5 |
Maximum | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Deferral percentage of base salary (as a percentage) | 80.00% | |
Deferral percentage of other compensation (as a percentage) | 100.00% |
Segment Data (Details)
Segment Data (Details) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021USD ($)segment | Mar. 31, 2020USD ($) | |
Segment Reporting Information [Line Items] | ||
Number of reportable segments of company | segment | 2 | |
Net sales | $ 195,019 | $ 147,162 |
Cost of sales | 71,666 | 58,554 |
Gross margin | 123,353 | 88,608 |
Research and development | 47,018 | 26,381 |
TASER | ||
Segment Reporting Information [Line Items] | ||
Net sales | 98,999 | 75,895 |
Cost of sales | 32,945 | 30,248 |
Gross margin | 66,054 | 45,647 |
Research and development | 9,243 | 3,032 |
Software and Sensors | ||
Segment Reporting Information [Line Items] | ||
Net sales | 96,020 | 71,267 |
Cost of sales | 38,721 | 28,306 |
Gross margin | 57,299 | 42,961 |
Research and development | 37,775 | 23,349 |
Product | ||
Segment Reporting Information [Line Items] | ||
Net sales | 140,886 | 107,288 |
Cost of sales | 58,616 | 48,884 |
Product | TASER | ||
Segment Reporting Information [Line Items] | ||
Net sales | 97,302 | 75,175 |
Cost of sales | 32,945 | 30,248 |
Product | Software and Sensors | ||
Segment Reporting Information [Line Items] | ||
Net sales | 43,584 | 32,113 |
Cost of sales | 25,671 | 18,636 |
Service | ||
Segment Reporting Information [Line Items] | ||
Net sales | 54,133 | 39,874 |
Cost of sales | 13,050 | 9,670 |
Service | TASER | ||
Segment Reporting Information [Line Items] | ||
Net sales | 1,697 | 720 |
Cost of sales | 0 | 0 |
Service | Software and Sensors | ||
Segment Reporting Information [Line Items] | ||
Net sales | 52,436 | 39,154 |
Cost of sales | $ 13,050 | $ 9,670 |